CLX 10-Q Quarterly Report March 31, 2020 | Alphaminr
ALPHAMINR

CLX 10-Q Quarter ended March 31, 2020

Balance Sheet
Cash Flow
Income Statement
Debt
CLOROX CO /DE/
10-Ks and 10-Qs
10-Q
Quarter ended Sept. 30, 2025
10-K
Fiscal year ended June 30, 2025
10-Q
Quarter ended March 31, 2025
10-Q
Quarter ended Dec. 31, 2024
10-Q
Quarter ended Sept. 30, 2024
10-K
Fiscal year ended June 30, 2024
10-Q
Quarter ended March 31, 2024
10-Q
Quarter ended Dec. 31, 2023
10-Q
Quarter ended Sept. 30, 2023
10-K
Fiscal year ended June 30, 2023
10-Q
Quarter ended March 31, 2023
10-Q
Quarter ended Dec. 31, 2022
10-Q
Quarter ended Sept. 30, 2022
10-K
Fiscal year ended June 30, 2022
10-Q
Quarter ended March 31, 2022
10-Q
Quarter ended Dec. 31, 2021
10-Q
Quarter ended Sept. 30, 2021
10-K
Fiscal year ended June 30, 2021
10-Q
Quarter ended March 31, 2021
10-Q
Quarter ended Dec. 31, 2020
10-Q
Quarter ended Sept. 30, 2020
10-K
Fiscal year ended June 30, 2020
10-Q
Quarter ended March 31, 2020
10-Q
Quarter ended Dec. 31, 2019
10-Q
Quarter ended Sept. 30, 2019
10-K
Fiscal year ended June 30, 2019
10-Q
Quarter ended March 31, 2019
10-Q
Quarter ended Dec. 31, 2018
10-Q
Quarter ended Sept. 30, 2018
10-K
Fiscal year ended June 30, 2018
10-Q
Quarter ended March 31, 2018
10-Q
Quarter ended Dec. 31, 2017
10-Q
Quarter ended Sept. 30, 2017
10-K
Fiscal year ended June 30, 2017
10-Q
Quarter ended March 31, 2017
10-Q
Quarter ended Dec. 31, 2016
10-Q
Quarter ended Sept. 30, 2016
10-K
Fiscal year ended June 30, 2016
10-Q
Quarter ended March 31, 2016
10-Q
Quarter ended Dec. 31, 2015
10-Q
Quarter ended Sept. 30, 2015
10-K
Fiscal year ended June 30, 2015
10-Q
Quarter ended March 31, 2015
10-Q
Quarter ended Dec. 31, 2014
10-Q
Quarter ended Sept. 30, 2014
10-K
Fiscal year ended June 30, 2014
10-Q
Quarter ended March 31, 2014
10-Q
Quarter ended Dec. 31, 2013
10-Q
Quarter ended Sept. 30, 2013
10-K
Fiscal year ended June 30, 2013
10-Q
Quarter ended March 31, 2013
10-Q
Quarter ended Dec. 31, 2012
10-Q
Quarter ended Sept. 30, 2012
10-K
Fiscal year ended June 30, 2012
10-Q
Quarter ended March 31, 2012
10-Q
Quarter ended Dec. 31, 2011
10-Q
Quarter ended Sept. 30, 2011
10-K
Fiscal year ended June 30, 2011
10-Q
Quarter ended March 31, 2011
10-Q
Quarter ended Dec. 31, 2010
10-Q
Quarter ended Sept. 30, 2010
10-K
Fiscal year ended June 30, 2010
10-Q
Quarter ended March 31, 2010
10-Q
Quarter ended Dec. 31, 2009
PROXIES
DEF 14A
Filed on Nov. 19, 2025
DEF 14A
Filed on Nov. 20, 2024
DEF 14A
Filed on Oct. 4, 2024
DEF 14A
Filed on Nov. 15, 2023
DEF 14A
Filed on Oct. 5, 2023
DEF 14A
Filed on Nov. 16, 2022
DEF 14A
Filed on Oct. 5, 2022
DEF 14A
Filed on Oct. 6, 2021
DEF 14A
Filed on Oct. 6, 2020
DEF 14A
Filed on Oct. 2, 2019
DEF 14A
Filed on Oct. 1, 2018
DEF 14A
Filed on Sept. 22, 2017
DEF 14A
Filed on Sept. 23, 2016
DEF 14A
Filed on Sept. 25, 2015
DEF 14A
Filed on Sept. 26, 2014
DEF 14A
Filed on Oct. 3, 2013
DEF 14A
Filed on Sept. 28, 2012
DEF 14A
Filed on Sept. 30, 2011
DEF 14A
Filed on Aug. 19, 2011
DEF 14A
Filed on Oct. 1, 2010
DEF 14A
Filed on None
clx-20200331
0000021076 false --06-30 Q3 2020 0000021076 2019-07-01 2020-03-31 xbrli:shares 0000021076 2020-04-17 iso4217:USD 0000021076 2020-01-01 2020-03-31 0000021076 2019-01-01 2019-03-31 0000021076 2018-07-01 2019-03-31 iso4217:USD xbrli:shares 0000021076 2020-03-31 0000021076 2019-06-30 0000021076 2018-06-30 0000021076 2019-03-31 0000021076 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2019-07-01 xbrli:pure 0000021076 clx:TotalCommodityPurchaseDerivativeContractsMember 2019-07-01 2020-03-31 0000021076 clx:TotalCommodityPurchaseDerivativeContractsMember 2020-03-31 0000021076 clx:SoybeanOilFuturesMember 2020-03-31 0000021076 clx:JetFuelSwapsMember 2020-03-31 0000021076 clx:TotalCommodityPurchaseDerivativeContractsMember 2019-06-30 0000021076 clx:SoybeanOilFuturesMember 2019-06-30 0000021076 clx:JetFuelSwapsMember 2019-06-30 0000021076 us-gaap:ForeignExchangeContractMember clx:PurchasesofInventoryMember 2020-03-31 0000021076 us-gaap:ForeignExchangeContractMember clx:PurchasesofInventoryMember 2019-06-30 clx:instrument 0000021076 us-gaap:CommodityContractMember 2020-01-01 2020-03-31 0000021076 us-gaap:CommodityContractMember 2019-01-01 2019-03-31 0000021076 us-gaap:CommodityContractMember 2019-07-01 2020-03-31 0000021076 us-gaap:CommodityContractMember 2018-07-01 2019-03-31 0000021076 us-gaap:ForeignExchangeContractMember 2020-01-01 2020-03-31 0000021076 us-gaap:ForeignExchangeContractMember 2019-01-01 2019-03-31 0000021076 us-gaap:ForeignExchangeContractMember 2019-07-01 2020-03-31 0000021076 us-gaap:ForeignExchangeContractMember 2018-07-01 2019-03-31 0000021076 us-gaap:InterestRateContractMember 2020-01-01 2020-03-31 0000021076 us-gaap:InterestRateContractMember 2019-01-01 2019-03-31 0000021076 us-gaap:InterestRateContractMember 2019-07-01 2020-03-31 0000021076 us-gaap:InterestRateContractMember 2018-07-01 2019-03-31 0000021076 us-gaap:CommodityContractMember us-gaap:CostOfSalesMember 2020-01-01 2020-03-31 0000021076 us-gaap:CommodityContractMember us-gaap:CostOfSalesMember 2019-01-01 2019-03-31 0000021076 us-gaap:CommodityContractMember us-gaap:CostOfSalesMember 2019-07-01 2020-03-31 0000021076 us-gaap:CommodityContractMember us-gaap:CostOfSalesMember 2018-07-01 2019-03-31 0000021076 us-gaap:ForeignExchangeContractMember us-gaap:CostOfSalesMember 2020-01-01 2020-03-31 0000021076 us-gaap:ForeignExchangeContractMember us-gaap:CostOfSalesMember 2019-01-01 2019-03-31 0000021076 us-gaap:ForeignExchangeContractMember us-gaap:CostOfSalesMember 2019-07-01 2020-03-31 0000021076 us-gaap:ForeignExchangeContractMember us-gaap:CostOfSalesMember 2018-07-01 2019-03-31 0000021076 us-gaap:InterestExpenseMember us-gaap:InterestRateContractMember 2020-01-01 2020-03-31 0000021076 us-gaap:InterestExpenseMember us-gaap:InterestRateContractMember 2019-01-01 2019-03-31 0000021076 us-gaap:InterestExpenseMember us-gaap:InterestRateContractMember 2019-07-01 2020-03-31 0000021076 us-gaap:InterestExpenseMember us-gaap:InterestRateContractMember 2018-07-01 2019-03-31 0000021076 us-gaap:CommodityContractMember clx:SoybeanOilFuturesMember 2020-03-31 0000021076 us-gaap:CommodityContractMember clx:SoybeanOilFuturesMember 2019-06-30 0000021076 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:ForeignExchangeContractMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:FairValueInputsLevel2Member 2020-03-31 0000021076 us-gaap:ForeignExchangeContractMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-03-31 0000021076 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:ForeignExchangeContractMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:FairValueInputsLevel2Member 2019-06-30 0000021076 us-gaap:ForeignExchangeContractMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-06-30 0000021076 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-03-31 0000021076 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-03-31 0000021076 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-06-30 0000021076 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-06-30 0000021076 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:CommodityContractMember us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:FairValueInputsLevel2Member 2020-03-31 0000021076 us-gaap:CommodityContractMember us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-03-31 0000021076 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:CommodityContractMember us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:FairValueInputsLevel2Member 2019-06-30 0000021076 us-gaap:CommodityContractMember us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-06-30 0000021076 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:CommodityContractMember us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:FairValueInputsLevel1Member 2020-03-31 0000021076 us-gaap:CommodityContractMember us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-03-31 0000021076 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:CommodityContractMember us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:FairValueInputsLevel1Member 2019-06-30 0000021076 us-gaap:CommodityContractMember us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-06-30 0000021076 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:CommodityContractMember us-gaap:FairValueInputsLevel2Member us-gaap:OtherLiabilitiesMember 2020-03-31 0000021076 us-gaap:CommodityContractMember us-gaap:FairValueInputsLevel2Member us-gaap:OtherLiabilitiesMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-03-31 0000021076 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:CommodityContractMember us-gaap:FairValueInputsLevel2Member us-gaap:OtherLiabilitiesMember 2019-06-30 0000021076 us-gaap:CommodityContractMember us-gaap:FairValueInputsLevel2Member us-gaap:OtherLiabilitiesMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-06-30 0000021076 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2020-03-31 0000021076 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-03-31 0000021076 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2019-06-30 0000021076 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-06-30 0000021076 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:BankTimeDepositsMember 2020-03-31 0000021076 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:BankTimeDepositsMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-03-31 0000021076 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:BankTimeDepositsMember 2019-06-30 0000021076 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:BankTimeDepositsMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-06-30 0000021076 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:OtherAssetsMember us-gaap:FairValueInputsLevel1Member clx:TrustAssetsForNonqualifiedDeferredCompensationPlansMember 2020-03-31 0000021076 us-gaap:OtherAssetsMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember clx:TrustAssetsForNonqualifiedDeferredCompensationPlansMember 2020-03-31 0000021076 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:OtherAssetsMember us-gaap:FairValueInputsLevel1Member clx:TrustAssetsForNonqualifiedDeferredCompensationPlansMember 2019-06-30 0000021076 us-gaap:OtherAssetsMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember clx:TrustAssetsForNonqualifiedDeferredCompensationPlansMember 2019-06-30 0000021076 us-gaap:NotesPayableOtherPayablesMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueInputsLevel2Member clx:NotesAndLoansPayableMember 2020-03-31 0000021076 us-gaap:NotesPayableOtherPayablesMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember clx:NotesAndLoansPayableMember 2020-03-31 0000021076 us-gaap:NotesPayableOtherPayablesMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueInputsLevel2Member clx:NotesAndLoansPayableMember 2019-06-30 0000021076 us-gaap:NotesPayableOtherPayablesMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember clx:NotesAndLoansPayableMember 2019-06-30 0000021076 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueInputsLevel2Member clx:CurrentMaturitiesOfLongTermDebtAndLongTermDebtMember us-gaap:LongTermDebtMember 2020-03-31 0000021076 us-gaap:FairValueInputsLevel2Member clx:CurrentMaturitiesOfLongTermDebtAndLongTermDebtMember us-gaap:LongTermDebtMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-03-31 0000021076 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueInputsLevel2Member clx:CurrentMaturitiesOfLongTermDebtAndLongTermDebtMember us-gaap:LongTermDebtMember 2019-06-30 0000021076 us-gaap:FairValueInputsLevel2Member clx:CurrentMaturitiesOfLongTermDebtAndLongTermDebtMember us-gaap:LongTermDebtMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-06-30 0000021076 clx:RevolvingCreditAgreementMaturesNovember2024Member us-gaap:LineOfCreditMember us-gaap:RevolvingCreditFacilityMember 2019-11-15 0000021076 clx:RevolvingCreditAgreementMaturesFebruary2022Member us-gaap:LineOfCreditMember us-gaap:RevolvingCreditFacilityMember 2017-02-08 0000021076 clx:RevolvingCreditAgreementMaturesNovember2024Member us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2020-03-31 0000021076 clx:RevolvingCreditAgreementMaturesNovember2024Member us-gaap:LineOfCreditMember us-gaap:RevolvingCreditFacilityMember 2019-06-30 0000021076 us-gaap:CommonStockMember 2018-12-31 0000021076 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000021076 us-gaap:RetainedEarningsMember 2018-12-31 0000021076 us-gaap:TreasuryStockMember 2018-12-31 0000021076 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000021076 2018-12-31 0000021076 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0000021076 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0000021076 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0000021076 us-gaap:TreasuryStockMember 2019-01-01 2019-03-31 0000021076 us-gaap:CommonStockMember 2019-03-31 0000021076 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0000021076 us-gaap:RetainedEarningsMember 2019-03-31 0000021076 us-gaap:TreasuryStockMember 2019-03-31 0000021076 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0000021076 us-gaap:CommonStockMember 2019-12-31 0000021076 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000021076 us-gaap:RetainedEarningsMember 2019-12-31 0000021076 us-gaap:TreasuryStockMember 2019-12-31 0000021076 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000021076 2019-12-31 0000021076 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0000021076 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0000021076 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0000021076 us-gaap:TreasuryStockMember 2020-01-01 2020-03-31 0000021076 us-gaap:CommonStockMember 2020-03-31 0000021076 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0000021076 us-gaap:RetainedEarningsMember 2020-03-31 0000021076 us-gaap:TreasuryStockMember 2020-03-31 0000021076 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0000021076 us-gaap:CommonStockMember 2018-06-30 0000021076 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0000021076 us-gaap:RetainedEarningsMember 2018-06-30 0000021076 us-gaap:TreasuryStockMember 2018-06-30 0000021076 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-06-30 0000021076 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2018-07-01 0000021076 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2018-07-01 0000021076 us-gaap:RetainedEarningsMember 2018-07-01 2019-03-31 0000021076 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-07-01 2019-03-31 0000021076 us-gaap:AdditionalPaidInCapitalMember 2018-07-01 2019-03-31 0000021076 us-gaap:TreasuryStockMember 2018-07-01 2019-03-31 0000021076 us-gaap:CommonStockMember 2019-06-30 0000021076 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0000021076 us-gaap:RetainedEarningsMember 2019-06-30 0000021076 us-gaap:TreasuryStockMember 2019-06-30 0000021076 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0000021076 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2019-07-01 0000021076 us-gaap:RetainedEarningsMember 2019-07-01 2020-03-31 0000021076 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-01 2020-03-31 0000021076 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2020-03-31 0000021076 us-gaap:TreasuryStockMember 2019-07-01 2020-03-31 clx:repurchase_program 0000021076 clx:A2BillionOpenMarketPurchaseProgramMember 2020-03-31 0000021076 clx:EvergreenProgramMember 2020-03-31 0000021076 clx:A2BillionOpenMarketPurchaseProgramMember 2020-01-01 2020-03-31 0000021076 clx:A2BillionOpenMarketPurchaseProgramMember 2019-01-01 2019-03-31 0000021076 clx:A2BillionOpenMarketPurchaseProgramMember 2019-07-01 2020-03-31 0000021076 clx:A2BillionOpenMarketPurchaseProgramMember 2018-07-01 2019-03-31 0000021076 clx:EvergreenProgramMember 2020-01-01 2020-03-31 0000021076 clx:EvergreenProgramMember 2019-01-01 2019-03-31 0000021076 clx:EvergreenProgramMember 2019-07-01 2020-03-31 0000021076 clx:EvergreenProgramMember 2018-07-01 2019-03-31 0000021076 us-gaap:AccumulatedTranslationAdjustmentMember 2018-12-31 0000021076 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-12-31 0000021076 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-12-31 0000021076 us-gaap:AccumulatedTranslationAdjustmentMember 2019-01-01 2019-03-31 0000021076 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-01-01 2019-03-31 0000021076 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-01-01 2019-03-31 0000021076 us-gaap:AccumulatedTranslationAdjustmentMember 2019-03-31 0000021076 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-03-31 0000021076 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-03-31 0000021076 us-gaap:AccumulatedTranslationAdjustmentMember 2019-12-31 0000021076 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-12-31 0000021076 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-12-31 0000021076 us-gaap:AccumulatedTranslationAdjustmentMember 2020-01-01 2020-03-31 0000021076 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-01-01 2020-03-31 0000021076 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-01-01 2020-03-31 0000021076 us-gaap:AccumulatedTranslationAdjustmentMember 2020-03-31 0000021076 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-03-31 0000021076 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-03-31 0000021076 us-gaap:AccumulatedTranslationAdjustmentMember 2018-06-30 0000021076 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-06-30 0000021076 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-06-30 0000021076 us-gaap:AccumulatedTranslationAdjustmentMember 2018-07-01 2019-03-31 0000021076 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-07-01 2019-03-31 0000021076 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-07-01 2019-03-31 0000021076 us-gaap:AccumulatedTranslationAdjustmentMember 2019-06-30 0000021076 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-06-30 0000021076 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-06-30 0000021076 us-gaap:AccumulatedTranslationAdjustmentMember 2019-07-01 2020-03-31 0000021076 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-07-01 2020-03-31 0000021076 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-07-01 2020-03-31 0000021076 clx:LongTermInterCompanyLoansMember 2020-01-01 2020-03-31 0000021076 clx:LongTermInterCompanyLoansMember 2019-07-01 2020-03-31 0000021076 clx:LongTermInterCompanyLoansMember 2019-01-01 2019-03-31 0000021076 clx:LongTermInterCompanyLoansMember 2018-07-01 2019-03-31 0000021076 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember clx:RetirementIncomeMember 2020-01-01 2020-03-31 0000021076 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember clx:RetirementIncomeMember 2019-01-01 2019-03-31 0000021076 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember clx:RetirementIncomeMember 2019-07-01 2020-03-31 0000021076 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember clx:RetirementIncomeMember 2018-07-01 2019-03-31 0000021076 country:US clx:RetirementIncomeMember 2020-01-01 2020-03-31 0000021076 country:US clx:RetirementIncomeMember 2019-07-01 2020-03-31 0000021076 country:US clx:RetirementIncomeMember 2019-01-01 2019-03-31 0000021076 country:US clx:RetirementIncomeMember 2018-07-01 2019-03-31 0000021076 clx:AlamedaCountyCaliforniaMatterMember 2020-03-31 0000021076 clx:AlamedaCountyCaliforniaMatterMember 2019-06-30 0000021076 clx:AlamedaCountyCaliforniaMatterMember 2019-07-01 2020-03-31 0000021076 clx:AlamedaCountyCaliforniaMatterMember 2017-06-30 0000021076 clx:DickinsonCountyMichiganMatterMember 2020-03-31 0000021076 clx:DickinsonCountyMichiganMatterMember 2019-06-30 0000021076 clx:DickinsonCountyMichiganMatterMember 2019-07-01 2020-03-31 clx:reportable_segment 0000021076 us-gaap:OperatingSegmentsMember clx:CleaningMember 2020-01-01 2020-03-31 0000021076 us-gaap:OperatingSegmentsMember clx:CleaningMember 2019-01-01 2019-03-31 0000021076 us-gaap:OperatingSegmentsMember clx:CleaningMember 2019-07-01 2020-03-31 0000021076 us-gaap:OperatingSegmentsMember clx:CleaningMember 2018-07-01 2019-03-31 0000021076 us-gaap:OperatingSegmentsMember clx:HouseholdMember 2020-01-01 2020-03-31 0000021076 us-gaap:OperatingSegmentsMember clx:HouseholdMember 2019-01-01 2019-03-31 0000021076 us-gaap:OperatingSegmentsMember clx:HouseholdMember 2019-07-01 2020-03-31 0000021076 us-gaap:OperatingSegmentsMember clx:HouseholdMember 2018-07-01 2019-03-31 0000021076 us-gaap:OperatingSegmentsMember clx:LifestyleMember 2020-01-01 2020-03-31 0000021076 us-gaap:OperatingSegmentsMember clx:LifestyleMember 2019-01-01 2019-03-31 0000021076 us-gaap:OperatingSegmentsMember clx:LifestyleMember 2019-07-01 2020-03-31 0000021076 us-gaap:OperatingSegmentsMember clx:LifestyleMember 2018-07-01 2019-03-31 0000021076 us-gaap:OperatingSegmentsMember clx:InternationalMember 2020-01-01 2020-03-31 0000021076 us-gaap:OperatingSegmentsMember clx:InternationalMember 2019-01-01 2019-03-31 0000021076 us-gaap:OperatingSegmentsMember clx:InternationalMember 2019-07-01 2020-03-31 0000021076 us-gaap:OperatingSegmentsMember clx:InternationalMember 2018-07-01 2019-03-31 0000021076 us-gaap:CorporateNonSegmentMember 2020-01-01 2020-03-31 0000021076 us-gaap:CorporateNonSegmentMember 2019-01-01 2019-03-31 0000021076 us-gaap:CorporateNonSegmentMember 2019-07-01 2020-03-31 0000021076 us-gaap:CorporateNonSegmentMember 2018-07-01 2019-03-31 0000021076 us-gaap:SalesRevenueNetMember clx:WalmartStoresIncMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-03-31 0000021076 us-gaap:SalesRevenueNetMember clx:WalmartStoresIncMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-03-31 0000021076 us-gaap:SalesRevenueNetMember clx:WalmartStoresIncMember us-gaap:CustomerConcentrationRiskMember 2018-07-01 2019-03-31 0000021076 us-gaap:SalesRevenueNetMember clx:WalmartStoresIncMember us-gaap:CustomerConcentrationRiskMember 2019-07-01 2020-03-31 0000021076 us-gaap:RevenueFromContractWithCustomerMember clx:CleaningMember us-gaap:ProductConcentrationRiskMember clx:HomeCareMember 2020-01-01 2020-03-31 0000021076 us-gaap:RevenueFromContractWithCustomerMember clx:CleaningMember us-gaap:ProductConcentrationRiskMember clx:HomeCareMember 2019-01-01 2019-03-31 0000021076 us-gaap:RevenueFromContractWithCustomerMember clx:CleaningMember us-gaap:ProductConcentrationRiskMember clx:HomeCareMember 2019-07-01 2020-03-31 0000021076 us-gaap:RevenueFromContractWithCustomerMember clx:CleaningMember us-gaap:ProductConcentrationRiskMember clx:HomeCareMember 2018-07-01 2019-03-31 0000021076 us-gaap:RevenueFromContractWithCustomerMember clx:CleaningMember us-gaap:ProductConcentrationRiskMember clx:LaundryMember 2020-01-01 2020-03-31 0000021076 us-gaap:RevenueFromContractWithCustomerMember clx:CleaningMember us-gaap:ProductConcentrationRiskMember clx:LaundryMember 2019-01-01 2019-03-31 0000021076 us-gaap:RevenueFromContractWithCustomerMember clx:CleaningMember us-gaap:ProductConcentrationRiskMember clx:LaundryMember 2019-07-01 2020-03-31 0000021076 us-gaap:RevenueFromContractWithCustomerMember clx:CleaningMember us-gaap:ProductConcentrationRiskMember clx:LaundryMember 2018-07-01 2019-03-31 0000021076 clx:ProfessionalProductsMember us-gaap:RevenueFromContractWithCustomerMember clx:CleaningMember us-gaap:ProductConcentrationRiskMember 2020-01-01 2020-03-31 0000021076 clx:ProfessionalProductsMember us-gaap:RevenueFromContractWithCustomerMember clx:CleaningMember us-gaap:ProductConcentrationRiskMember 2019-01-01 2019-03-31 0000021076 clx:ProfessionalProductsMember us-gaap:RevenueFromContractWithCustomerMember clx:CleaningMember us-gaap:ProductConcentrationRiskMember 2019-07-01 2020-03-31 0000021076 clx:ProfessionalProductsMember us-gaap:RevenueFromContractWithCustomerMember clx:CleaningMember us-gaap:ProductConcentrationRiskMember 2018-07-01 2019-03-31 0000021076 us-gaap:RevenueFromContractWithCustomerMember clx:CleaningMember us-gaap:ProductConcentrationRiskMember 2020-01-01 2020-03-31 0000021076 us-gaap:RevenueFromContractWithCustomerMember clx:CleaningMember us-gaap:ProductConcentrationRiskMember 2019-01-01 2019-03-31 0000021076 us-gaap:RevenueFromContractWithCustomerMember clx:CleaningMember us-gaap:ProductConcentrationRiskMember 2019-07-01 2020-03-31 0000021076 us-gaap:RevenueFromContractWithCustomerMember clx:CleaningMember us-gaap:ProductConcentrationRiskMember 2018-07-01 2019-03-31 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HouseholdMember clx:BagsWrapsAndContainersMember 2020-01-01 2020-03-31 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HouseholdMember clx:BagsWrapsAndContainersMember 2019-01-01 2019-03-31 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HouseholdMember clx:BagsWrapsAndContainersMember 2019-07-01 2020-03-31 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HouseholdMember clx:BagsWrapsAndContainersMember 2018-07-01 2019-03-31 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:CatLitterMember clx:HouseholdMember 2020-01-01 2020-03-31 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:CatLitterMember clx:HouseholdMember 2019-01-01 2019-03-31 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:CatLitterMember clx:HouseholdMember 2019-07-01 2020-03-31 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:CatLitterMember clx:HouseholdMember 2018-07-01 2019-03-31 0000021076 clx:GrillingMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HouseholdMember 2020-01-01 2020-03-31 0000021076 clx:GrillingMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HouseholdMember 2019-01-01 2019-03-31 0000021076 clx:GrillingMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HouseholdMember 2019-07-01 2020-03-31 0000021076 clx:GrillingMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HouseholdMember 2018-07-01 2019-03-31 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HouseholdMember clx:DigestiveHealthMember 2020-01-01 2020-03-31 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HouseholdMember clx:DigestiveHealthMember 2019-01-01 2019-03-31 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HouseholdMember clx:DigestiveHealthMember 2019-07-01 2020-03-31 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HouseholdMember clx:DigestiveHealthMember 2018-07-01 2019-03-31 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HouseholdMember 2020-01-01 2020-03-31 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HouseholdMember 2019-01-01 2019-03-31 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HouseholdMember 2019-07-01 2020-03-31 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HouseholdMember 2018-07-01 2019-03-31 0000021076 us-gaap:RevenueFromContractWithCustomerMember clx:LifestyleMember us-gaap:ProductConcentrationRiskMember clx:FoodProductsMember 2020-01-01 2020-03-31 0000021076 us-gaap:RevenueFromContractWithCustomerMember clx:LifestyleMember us-gaap:ProductConcentrationRiskMember clx:FoodProductsMember 2019-01-01 2019-03-31 0000021076 us-gaap:RevenueFromContractWithCustomerMember clx:LifestyleMember us-gaap:ProductConcentrationRiskMember clx:FoodProductsMember 2019-07-01 2020-03-31 0000021076 us-gaap:RevenueFromContractWithCustomerMember clx:LifestyleMember us-gaap:ProductConcentrationRiskMember clx:FoodProductsMember 2018-07-01 2019-03-31 0000021076 clx:NaturalPersonalCareMember us-gaap:RevenueFromContractWithCustomerMember clx:LifestyleMember us-gaap:ProductConcentrationRiskMember 2020-01-01 2020-03-31 0000021076 clx:NaturalPersonalCareMember us-gaap:RevenueFromContractWithCustomerMember clx:LifestyleMember us-gaap:ProductConcentrationRiskMember 2019-01-01 2019-03-31 0000021076 clx:NaturalPersonalCareMember us-gaap:RevenueFromContractWithCustomerMember clx:LifestyleMember us-gaap:ProductConcentrationRiskMember 2019-07-01 2020-03-31 0000021076 clx:NaturalPersonalCareMember us-gaap:RevenueFromContractWithCustomerMember clx:LifestyleMember us-gaap:ProductConcentrationRiskMember 2018-07-01 2019-03-31 0000021076 us-gaap:RevenueFromContractWithCustomerMember clx:LifestyleMember us-gaap:ProductConcentrationRiskMember clx:WaterFiltrationMember 2020-01-01 2020-03-31 0000021076 us-gaap:RevenueFromContractWithCustomerMember clx:LifestyleMember us-gaap:ProductConcentrationRiskMember clx:WaterFiltrationMember 2019-01-01 2019-03-31 0000021076 us-gaap:RevenueFromContractWithCustomerMember clx:LifestyleMember us-gaap:ProductConcentrationRiskMember clx:WaterFiltrationMember 2019-07-01 2020-03-31 0000021076 us-gaap:RevenueFromContractWithCustomerMember clx:LifestyleMember us-gaap:ProductConcentrationRiskMember clx:WaterFiltrationMember 2018-07-01 2019-03-31 0000021076 us-gaap:RevenueFromContractWithCustomerMember clx:LifestyleMember us-gaap:ProductConcentrationRiskMember clx:DietarySupplementsMember 2020-01-01 2020-03-31 0000021076 us-gaap:RevenueFromContractWithCustomerMember clx:LifestyleMember us-gaap:ProductConcentrationRiskMember clx:DietarySupplementsMember 2019-01-01 2019-03-31 0000021076 us-gaap:RevenueFromContractWithCustomerMember clx:LifestyleMember us-gaap:ProductConcentrationRiskMember clx:DietarySupplementsMember 2019-07-01 2020-03-31 0000021076 us-gaap:RevenueFromContractWithCustomerMember clx:LifestyleMember us-gaap:ProductConcentrationRiskMember clx:DietarySupplementsMember 2018-07-01 2019-03-31 0000021076 us-gaap:RevenueFromContractWithCustomerMember clx:LifestyleMember us-gaap:ProductConcentrationRiskMember 2020-01-01 2020-03-31 0000021076 us-gaap:RevenueFromContractWithCustomerMember clx:LifestyleMember us-gaap:ProductConcentrationRiskMember 2019-01-01 2019-03-31 0000021076 us-gaap:RevenueFromContractWithCustomerMember clx:LifestyleMember us-gaap:ProductConcentrationRiskMember 2019-07-01 2020-03-31 0000021076 us-gaap:RevenueFromContractWithCustomerMember clx:LifestyleMember us-gaap:ProductConcentrationRiskMember 2018-07-01 2019-03-31 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:InternationalMember 2020-01-01 2020-03-31 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:InternationalMember 2019-01-01 2019-03-31 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:InternationalMember 2019-07-01 2020-03-31 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:InternationalMember 2018-07-01 2019-03-31 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember 2020-01-01 2020-03-31 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember 2019-01-01 2019-03-31 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember 2019-07-01 2020-03-31 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember 2018-07-01 2019-03-31


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2020 .
OR
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                to
Commission File Number: 1-07151
_________________________
THE CLOROX COMPANY
(Exact name of registrant as specified in its charter)
Delaware 31-0595760
(State or other jurisdiction of (I.R.S. Employer Identification No.)
incorporation or organization)
1221 Broadway , Oakland , California , 94612-1888
(Address of principal executive offices) (Zip code)
( 510 ) 271-7000
(Registrant’s telephone number, including area code)
(Former name, former address and former fiscal year, if changed since last report)
___________________
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock - $1.00 par value CLX New York Stock Exchange
Securities registered pursuant to Section 12(g) of the Act: None
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☑ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer ☑ Accelerated filer ☐ Non-accelerated filer ☐ Smaller Reporting Company ☐ Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☑
As of April 17, 2020, there were 125,933,818 shares outstanding of the registrant’s common stock ($1.00 par value).



PART I – FINANCIAL INFORMATION

Item 1. Financial Statements
The Clorox Company
Condensed Consolidated Statements of Earnings and Comprehensive Income (Unaudited)
(Dollars in millions, except share and per share data)
Three Months Ended Nine Months Ended
3/31/2020 3/31/2019 3/31/2020 3/31/2019
Net sales $ 1,783 $ 1,551 $ 4,738 $ 4,587
Cost of products sold 951 878 2,604 2,593
Gross profit 832 673 2,134 1,994
Selling and administrative expenses 269 216 690 639
Advertising costs 184 161 461 445
Research and development costs 39 34 103 98
Interest expense 24 24 74 72
Other (income) expense, net 19 ( 2 ) 16 8
Earnings before income taxes 297 240 790 732
Income taxes 56 53 161 153
Net earnings $ 241 $ 187 $ 629 $ 579
Net earnings per share
Basic net earnings per share $ 1.92 $ 1.46 $ 5.01 $ 4.53
Diluted net earnings per share $ 1.89 $ 1.44 $ 4.94 $ 4.45
Weighted average shares outstanding (in thousands)
Basic 125,661 128,404 125,641 128,092
Diluted 127,328 130,266 127,236 130,218
Comprehensive income $ 186 $ 200 $ 575 $ 562

See Notes to Condensed Consolidated Financial Statements (Unaudited)
2

The Clorox Company
Condensed Consolidated Balance Sheets
(Dollars in millions, except share and per share data)
3/31/2020 6/30/2019
(Unaudited)
ASSETS
Current assets
Cash and cash equivalents $ 496 $ 111
Receivables, net 726 631
Inventories, net 457 512
Prepaid expenses and other current assets 71 51
Total current assets 1,750 1,305
Property, plant and equipment, net of accumulated depreciation and amortization
of $ 2,203 and $ 2,150 , respectively
1,047 1,034
Operating lease right-of-use assets 297 —
Goodwill 1,568 1,591
Trademarks, net 785 791
Other intangible assets, net 111 121
Other assets 292 274
Total assets $ 5,850 $ 5,116
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities
Notes and loans payable $ 638 $ 396
Current operating lease liabilities 65 —
Accounts payable and accrued liabilities 1,091 1,035
Income taxes payable — 9
Total current liabilities 1,794 1,440
Long-term debt 2,288 2,287
Long-term operating lease liabilities 277 —
Other liabilities 730 780
Deferred income taxes 66 50
Total liabilities 5,155 4,557
Commitments and contingencies
Stockholders’ equity
Preferred stock: $ 1.00 par value; 5,000,000 shares authorized; none
issued or outstanding
— —
Common stock: $ 1.00 par value; 750,000,000 shares authorized; 158,741,461 shares
issued as of March 31, 2020 and June 30, 2019; and 125,923,030 and 125,686,325 shares outstanding as of March 31, 2020 and June 30, 2019, respectively
159 159
Additional paid-in capital 1,111 1,046
Retained earnings 3,398 3,150
Treasury shares, at cost: 32,818,431 and 33,055,136 shares as of March 31, 2020
and June 30, 2019, respectively
( 3,317 ) ( 3,194 )
Accumulated other comprehensive net (loss) income ( 656 ) ( 602 )
Stockholders’ equity 695 559
Total liabilities and stockholders’ equity $ 5,850 $ 5,116

See Notes to Condensed Consolidated Financial Statements (Unaudited)
3

The Clorox Company
Condensed Consolidated Statements of Cash Flows (Unaudited)
(Dollars in millions)
Nine Months Ended
3/31/2020 3/31/2019
Operating activities:
Net earnings $ 629 $ 579
Adjustments to reconcile net earnings to net cash provided by operations:
Depreciation and amortization 133 133
Stock-based compensation 37 34
Deferred income taxes 5 ( 7 )
Other 26 ( 29 )
Changes in:
Receivables, net ( 102 ) 11
Inventories, net 50 ( 51 )
Prepaid expenses and other current assets ( 6 ) ( 10 )
Accounts payable and accrued liabilities 53 ( 55 )
Operating lease right-of-use assets and liabilities, net 7 —
Income taxes payable / prepaid ( 26 ) ( 2 )
Net cash provided by operations 806 603
Investing activities:
Capital expenditures ( 158 ) ( 135 )
Other 13 9
Net cash used for investing activities ( 145 ) ( 126 )
Financing activities:
Notes and loans payable, net 234 117
Treasury stock purchased ( 225 ) ( 315 )
Cash dividends paid ( 399 ) ( 368 )
Issuance of common stock for employee stock plans and other 129 137
Net cash used for financing activities ( 261 ) ( 429 )
Effect of exchange rate changes on cash, cash equivalents, and restricted cash ( 8 ) ( 2 )
Net increase (decrease) in cash, cash equivalents, and restricted cash 392 46
Cash, cash equivalents, and restricted cash:
Beginning of period 113 134
End of period $ 505 $ 180


See Notes to Condensed Consolidated Financial Statements (Unaudited)
4

The Clorox Company
Notes to Condensed Consolidated Financial Statements (Unaudited)
(Dollars in millions, except share and per share data)

NOTE 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The unaudited interim condensed consolidated financial statements for the three and nine months ended March 31, 2020 and 2019, in the opinion of management, reflect all adjustments (consisting of normal recurring accruals) necessary for a fair presentation of the consolidated results of operations, financial position and cash flows of The Clorox Company and its subsidiaries (the Company) for the periods presented. However, the financial results for interim periods are not necessarily indicative of the results that may be expected for a full fiscal year or for any other future period.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) have been omitted or condensed pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC). The information in this report should be read in conjunction with the Company’s Annual Report on Form 10-K filed with the SEC for the fiscal year ended June 30, 2019, which includes a complete set of footnote disclosures, including the Company’s significant accounting policies.

Leases

Effective July 1, 2019, the Company adopted Accounting Standards Codification 842, Leases (ASC 842). Under this guidance, the Company determines whether an arrangement contains a lease at inception by determining if the contract conveys the right to control the use of identified property, plant or equipment for a period of time in exchange for consideration and other facts and circumstances. Right-of-use (ROU) assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. ROU assets are calculated based on the lease liability adjusted for any lease payments paid to the lessor at or before the commencement date and initial direct costs incurred by the Company and excludes any lease incentives received from the lessor. Lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term. The lease term may include an option to extend or terminate the lease when it is reasonably certain that the Company will exercise that option as of the commencement date of the lease, and is reviewed in subsequent periods if a triggering event occurs. As the Company’s leases typically do not contain a readily determinable implicit rate, the Company determines the present value of the lease liability using its incremental borrowing rate at the lease commencement date based on the lease term and the currency of the lease on a collateralized basis. Variable lease payments are the portion of lease payments that are not fixed over the lease term. Variable lease payments are expensed as incurred, and include certain non-lease components, such as maintenance and other services provided by the lessor, and other charges included in the lease, as applicable. The Company elected to combine lease and non-lease components as a single lease component and to exclude short-term leases, defined as leases with initial terms of 12 months or less, from its condensed consolidated balance sheet.


5
NOTE 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)
Recently Issued Accounting Standards

Recently Issued Accounting Standards Not Yet Adopted

In December 2019, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes,” which simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and clarifies and amends existing guidance to improve consistency of application. The standard will be effective for the Company beginning in the first quarter of fiscal year 2022, with early adoption permitted. The Company is currently evaluating the impact that the adoption of this guidance will have on its consolidated financial statements.

In January 2017, the FASB issued ASU No. 2017-04, “Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment,” which eliminates the requirement to calculate the implied fair value of goodwill to measure a goodwill impairment charge. The new guidance is effective for the Company beginning in the first quarter of fiscal year 2021, with early adoption permitted. The Company intends to adopt the standard no later than July 1, 2020. The impact of the new standard will be dependent on the specific facts and circumstances of future individual impairments, if any.

Recently Adopted Accounting Standards

In August 2017, the FASB issued ASU No. 2017-12, “Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities,” which amends the hedge accounting recognition and presentation requirements to better align an entity’s risk management activities with its financial reporting. This standard also simplifies the application of hedge accounting in certain situations. The Company adopted this new guidance in the first quarter of fiscal year 2020 and the adoption did not have a material impact on the Company’s consolidated financial statements.

In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842),” which requires lessees to recognize a ROU asset and a lease liability for all leases with terms of more than 12 months. Recognition, measurement and presentation will depend on the classification of a lease as either a finance or an operating lease. ASU 2016-02 also requires expanded disclosures about leasing arrangements. In July 2018, the FASB issued ASU No. 2018-11, “Leases (Topic 842), Targeted Improvements,” which provides an optional transition method in applying the new lease standard. Topic 842 can be applied using either a modified retrospective approach at the beginning of the earliest period presented, or, as permitted by ASU 2018-11, at the beginning of the period in which it is adopted. The Company adopted the new standard in the first quarter of fiscal year 2020, on a modified retrospective basis using the optional transition method, and, accordingly, has not restated comparative periods; fiscal year 2019 balances and related disclosures supporting those comparative period balances continue to be presented under ASC 840, “Leases.” As allowed under the new standard, the Company elected to apply the package of practical expedients to not reassess prior conclusions related to contracts containing leases, lease classification and initial direct costs. Upon adoption, the Company recorded a cumulative effect adjustment to the opening balance of Retained earnings of $ 22 related primarily to the remaining deferred gain from the sale-leaseback of the Company’s general office building in Oakland, California. This new standard did not have a material impact on the Company’s condensed consolidated statement of earnings or the condensed consolidated statement of cash flows. Refer to Note 3 for more information.

NOTE 2. INVENTORIES, NET
Inventories, net, consisted of the following as of:
3/31/2020 6/30/2019
Finished goods $ 362 $ 411
Raw materials and packaging 123 125
Work in process 7 6
LIFO allowances ( 35 ) ( 30 )
Total $ 457 $ 512

6

NOTE 3. LEASES AND OTHER COMMITMENTS

The Company leases various property, plant and equipment, including office, warehousing, manufacturing and research and development facilities and equipment. These leases have remaining lease terms of up to 11 years, inclusive of renewal or termination options that the Company is reasonably certain to exercise. The Company’s lease agreements do not contain any material residual value guarantees or material restrictive covenants.

Supplemental balance sheet information related to the Company’s leases was as follows:
Balance sheet classification 3/31/2020
Operating leases
Right-of-use assets Operating lease right-of-use assets $ 297
Current lease liabilities Current operating lease liabilities 65
Non-current lease liabilities Long-term operating lease liabilities 277
Total operating lease liabilities $ 342
Finance leases
Right-of-use assets Other assets $ 14
Current lease liabilities Accounts payable and accrued liabilities 2
Non-current lease liabilities Other liabilities 12
Total finance lease liabilities $ 14

Components of lease cost were as follows:
Three Months Ended Nine Months Ended
3/31/2020 3/31/2020
Operating lease cost $ 17 54
Finance lease cost:
Amortization of right-of-use assets 1 3
Interest on lease liabilities — —
Total finance lease cost $ 1 3
Variable lease cost $ 10 30
Short term lease cost — 1

7
NOTE 3. LEASES AND OTHER COMMITMENTS (Continued)
Supplemental cash flow information and non-cash activity related to the Company’s leases were as follows:
Nine Months Ended
3/31/2020
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases, net $ 47
Operating cash flows from finance leases —
Financing cash flows from finance leases 2
Right-of-use assets obtained in exchange for lease obligations:
Operating leases $ 28
Finance leases 7

Weighted-average remaining lease term and discount rate for the Company’s leases were as follows:
3/31/2020
Weighted-average remaining lease term:
Operating leases 7 years
Finance leases 7 years
Weighted-average discount rate:
Operating leases 2.6 %
Finance leases 3.2 %

Maturities of lease liabilities by fiscal year for the Company’s leases as of March 31, 2020 were as follows:
Year Operating leases Finance leases
2020 $ 12 $ 1
2021 68 3
2022 54 2
2023 48 2
2024 41 2
Thereafter 155 6
Total lease payments $ 378 $ 16
Less: Imputed interest ( 36 ) ( 2 )
Total lease liabilities $ 342 $ 14

The future minimum annual lease payments required under the Company’s existing non-cancelable operating and capital lease agreements as of June 30, 2019 prior to the adoption of ASC 842 were as follows:
Year Operating leases Capital leases
2020 $ 71 $ 2
2021 65 2
2022 50 1
2023 42 1
2024 37 1
Thereafter 124 2
Total lease payments $ 389 $ 9


8

NOTE 4. FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS

Financial Risk Management and Derivative Instruments

The Company is exposed to certain commodity, foreign currency and interest rate risks related to its ongoing business operations and uses derivative instruments to mitigate its exposure to these risks.

Commodity Price Risk Management

The Company may use commodity exchange traded futures and over-the-counter swap contracts, which are generally no longer than 2 years, to fix the price of a portion of its forecasted raw material requirements. Commodity purchase contracts are measured at fair value using market quotations obtained from the Chicago Board of Trade commodity futures exchange and commodity derivative dealers.

As of March 31, 2020, the notional amount of commodity derivatives was $ 31 , of which $ 18 related to soybean oil futures used for the Food products business and $ 13 related to jet fuel swaps used for the Grilling business. As of June 30, 2019, the notional amount of commodity derivatives was $ 24 , of which $ 13 related to soybean oil futures and $ 11 related to jet fuel swaps.

Foreign Currency Risk Management

The Company may also enter into certain over-the-counter derivative contracts to manage a portion of the Company’s forecasted foreign currency exposure associated with the purchase of inventory. These foreign currency contracts generally have durations of no longer than 2 years. The foreign exchange contracts are measured at fair value using information quoted by foreign exchange dealers.

The notional amounts of outstanding foreign currency forward contracts used by the Company’s subsidiaries to hedge forecasted purchases of inventory were $ 26 and $ 61 , respectively, as of March 31, 2020 and June 30, 2019.

Interest Rate Risk Management

The Company may enter into over-the-counter interest rate forward contracts to fix a portion of the benchmark interest rate prior to the anticipated issuance of fixed rate debt or to manage the Company’s level of fixed and floating rate debt. These interest rate forward contracts historically have had durations of less than 12 months. The interest rate contracts are measured at fair value using information quoted by U.S. government bond dealers.

As of March 31, 2020 and June 30, 2019, the Company had no outstanding interest rate forward contracts.
9
NOTE 4. FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Continued)
Commodity, Foreign Exchange and Interest Rate Derivatives

The Company designates its commodity forward and futures contracts for forecasted purchases of raw materials, foreign currency forward contracts for forecasted purchases of inventory and interest rate forward contracts for forecasted interest payments as cash flow hedges.

The effects of derivative instruments designated as hedging instruments on Other comprehensive (loss) income and Net earnings were as follows:

Gains (losses) recognized in Other comprehensive (loss) income
Three Months Ended Nine Months Ended
3/31/2020 3/31/2019 3/31/2020 3/31/2019
Commodity purchase derivative contracts $ ( 11 ) $ 2 $ ( 8 ) $ ( 4 )
Foreign exchange derivative contracts 2 — 2 1
Interest rate derivative contracts — — — —
Total $ ( 9 ) $ 2 $ ( 6 ) $ ( 3 )

Location of Gains (losses) reclassified from Accumulated other comprehensive net (loss) income into Net earnings Gains (losses) reclassified from Accumulated other comprehensive net (loss) income and recognized in Net earnings
Three Months Ended Nine Months Ended
3/31/2020 3/31/2019 3/31/2020 3/31/2019
Commodity purchase derivative contracts Cost of products sold $ — $ ( 1 ) $ ( 1 ) $ ( 1 )
Foreign exchange derivative contracts Cost of products sold — 1 — 2
Interest rate derivative contracts Interest expense ( 2 ) ( 2 ) ( 5 ) ( 5 )
Total $ ( 2 ) $ ( 2 ) $ ( 6 ) $ ( 4 )

The estimated amount of the existing net gain (loss) in Accumulated other comprehensive net (loss) income as of March 31, 2020, that is expected to be reclassified into Net earnings within the next twelve months is $( 11 ).

10
NOTE 4. FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Continued)
Counterparty Risk Management and Derivative Contract Requirements

The Company utilizes a variety of financial institutions as counterparties for over-the-counter derivative instruments. The Company enters into agreements governing the use of over-the-counter derivative instruments and sets internal limits on the aggregate over-the-counter derivative instrument positions held with each counterparty. Certain terms of these agreements require the Company or the counterparty to post collateral when the fair value of the derivative instrument exceeds contractually defined counterparty liability position limits. Of the over-the-counter derivative instruments in liability positions held as of both March 31, 2020 and June 30, 2019, $ 5 and $ 1 respectively, contained such terms. As of March 31, 2020 and June 30, 2019, neither the Company nor any counterparty was required to post any collateral as no counterparty liability position limits were exceeded.

Certain terms of the agreements governing the Company’s over-the-counter derivative instruments require the credit ratings of the Company and its counterparties, as assigned by Standard & Poor’s and Moody’s, to remain at a level equal to or better than the minimum of an investment grade credit rating. If the Company’s credit ratings were to fall below investment grade, the counterparties to the derivative instruments could request full collateralization on derivative instruments in net liability positions. As of both March 31, 2020 and June 30, 2019, the Company and each of its counterparties had been assigned investment grade credit ratings by both Standard & Poor’s and Moody’s.

Certain of the Company’s exchange-traded futures contracts used for commodity price risk management include requirements for the Company to post collateral in the form of a cash margin account held by the Company’s broker for trades conducted on that exchange. As of March 31, 2020 and June 30, 2019, the Company maintained a cash margin balance related to exchange-traded futures contracts of $ 2 and $ 1 , respectively, which is classified as Prepaid expenses and other current assets in the condensed consolidated balance sheets.

Trust Assets

The Company has held interests in mutual funds and cash equivalents as part of the trust assets related to its nonqualified deferred compensation plans. The participants in the nonqualified deferred compensation plans, who are the Company’s current and former employees, may select among certain mutual funds in which to invest their compensation deferrals in accordance with the terms of the plans and within the confines of the trusts, which hold the marketable securities. The trusts represent variable interest entities for which the Company is considered the primary beneficiary, and, therefore, trust assets are consolidated and included in Other assets in the condensed consolidated balance sheets. The interests in mutual funds are measured at fair value using quoted market prices. The Company has designated these marketable securities as trading investments.

Fair Value Measurements

Financial assets and liabilities measured at fair value on a recurring basis in the condensed consolidated balance sheets are required to be classified and disclosed in one of the following three categories of the fair value hierarchy:

Level 1: Quoted market prices in active markets for identical assets or liabilities.
Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.
Level 3: Unobservable inputs reflecting the reporting entity’s own assumptions.

As of March 31, 2020 and June 30, 2019, the Company’s financial assets and liabilities that were measured at fair value on a recurring basis included derivative financial instruments, which were classified as either Level 1 or Level 2, and trust assets to fund the Company’s nonqualified deferred compensation plans, which were classified as Level 1.
11
NOTE 4. FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Continued)
All of the Company’s derivative instruments qualify for hedge accounting. The following table provides information about the balance sheet classification and the fair values of the Company’s derivative instruments:
3/31/2020 6/30/2019
Balance sheet
classification 		Fair value
hierarchy
level 		Carrying
Amount 		Estimated
Fair
Value 		Carrying
Amount 		Estimated
Fair
Value
Assets
Foreign exchange forward contracts Prepaid expenses and other current assets 2 $ 2 $ 2 $ — $ —
$ 2 $ 2 $ — $ —
Liabilities
Commodity purchase swaps contracts Accounts payable and accrued liabilities 2 $ 5 $ 5 $ 1 $ 1
Commodity purchase futures contracts Accounts payable and accrued liabilities 1 1 1 1 1
Commodity purchase swaps contracts Other liabilities 2 1 1 — —
$ 7 $ 7 $ 2 $ 2

The following table provides information about the balance sheet classification and the fair values of the Company’s other assets and liabilities for which disclosure of fair value is required:
3/31/2020 6/30/2019
Balance sheet
classification 		Fair value
hierarchy
level 		Carrying
Amount 		Estimated
Fair
Value 		Carrying
Amount 		Estimated
Fair
Value
Assets
Investments, including money market funds
Cash and cash
equivalents (a)
1 $ 179 $ 179 $ 26 $ 26
Time deposits
Cash and cash
equivalents (a)
2 168 168 7 7
Trust assets for nonqualified deferred compensation plans Other assets 1 89 89 96 96
$ 436 $ 436 $ 129 $ 129
Liabilities
Notes and loans payable
Notes and loans payable (b)
2 $ 638 $ 638 $ 396 $ 396
Current maturities of long-term debt and Long-term debt
Current maturities of long-
term debt and Long-term
debt (c)
2 2,288 2,430 2,287 2,402
$ 2,926 $ 3,068 $ 2,683 $ 2,798

____________________

(a) Cash and cash equivalents are composed of time deposits and other interest bearing investments, including money market funds with original maturity dates of 90 days or less. Cash and cash equivalents are recorded at cost, which approximates fair value.
(b) Notes and loans payable is composed of amounts drawn on the Company’s Credit Agreement, outstanding U.S. commercial paper balances and/or other similar short-term debt issued by non-U.S. subsidiaries, all of which are recorded at cost, which approximates fair value.
(c) Current maturities of long-term debt and Long-term debt are recorded at cost. The fair value of Long-term debt, including current maturities, was determined using secondary market prices quoted by corporate bond dealers, and is classified as Level 2.

12

NOTE 5. DEBT

Short-term borrowings
Notes and loans payable, which mature in less than one year, consisted of the following as of:
3/31/2020 6/30/2019
Draw down on revolving credit facility $ 450 $ —
Commercial paper 188 396
Total $ 638 $ 396
On November 15, 2019, the Company entered into a new $ 1,200 revolving credit agreement (the Credit Agreement) that matures in November 2024. The Credit Agreement replaced a prior $ 1,100 revolving credit agreement (the Prior Agreement) in place since February 2017. No termination fees or penalties were incurred in connection with entering the new agreement, which was considered a debt modification.
There was $ 450 outstanding under the Credit Agreement as of March 31, 2020, and no borrowings under the Prior Agreement as of June 30, 2019. The Company borrowed under the Credit Agreement primarily to pay down maturing commercial paper balances in light of current uncertainty in short-term credit markets resulting from the COVID-19 outbreak. As of March 31, 2020, the effective interest of the revolving credit facility was 1.86 %.
The Company believes that borrowings under the new Credit Agreement will continue to be available for general corporate purposes. The new Credit Agreement includes certain restrictive covenants and limitations, which are consistent with the Prior Agreement and with which the Company was in compliance as of March 31, 2020.

NOTE 6. INCOME TAXES
In determining its quarterly provision for income taxes, the Company uses an estimated annual effective tax rate, which is based on expected annual income, statutory tax rates and tax planning opportunities available in the various jurisdictions in which the Company operates. Certain significant or unusual items are separately recognized in the quarter in which they occur and can be a source of variability in the effective tax rates from quarter to quarter. The effective tax rate on earnings was 18.9 % and 20.4 % for the three and nine months ended March 31, 2020, respectively, and 21.8 % and 20.8 % for the three and nine months ended March 31, 2019, respectively. The decrease in the effective tax rate on earnings for the current three month period was primarily due to a higher benefit from excess tax benefits, partially offset by a lower benefit from the release of uncertain tax positions. The decrease for the current nine month period was primarily due to a higher benefit from the release of uncertain tax positions, offset by a lower benefit from excess tax benefits.

NOTE 7. NET EARNINGS PER SHARE (EPS)
The following is the reconciliation of the weighted average number of shares outstanding (in thousands) used to calculate basic net EPS to those used to calculate diluted net EPS:
Three Months Ended Nine Months Ended
3/31/2020 3/31/2019 3/31/2020 3/31/2019
Basic 125,661 128,404 125,641 128,092
Dilutive effect of stock options and other 1,667 1,862 1,595 2,126
Diluted 127,328 130,266 127,236 130,218
Antidilutive stock options and other — 23 2 807







13


NOTE 8. COMPREHENSIVE INCOME
The following table provides a summary of Comprehensive income for the periods indicated:
Three Months Ended Nine Months Ended
3/31/2020 3/31/2019 3/31/2020 3/31/2019
Net earnings $ 241 $ 187 $ 629 $ 579
Other comprehensive (loss) income, net of tax:
Foreign currency translation adjustments ( 51 ) 8 ( 58 ) ( 23 )
Net unrealized gains (losses) on derivatives ( 5 ) 3 1 2
Pension and postretirement benefit adjustments 1 2 3 4
Total other comprehensive (loss) income, net of tax ( 55 ) 13 ( 54 ) ( 17 )
Comprehensive income $ 186 $ 200 $ 575 $ 562


14

NOTE 9. STOCKHOLDERS ’ EQUITY

Changes in the components of Stockholders’ equity were as follows for the periods indicated:
Three Months Ended March 31
Common Stock Additional Paid-in Capital Retained Earnings Treasury Stock Accumulated
Other
Comprehensive
Net (Loss) Income
Total Stockholders ’ Equity
Amount Shares
(in thousands) 		Amount Shares
(in thousands)
Balance as of December 31, 2018 $ 159 158,741 $ 1,014 $ 2,940 $ ( 2,794 ) ( 30,651 ) $ ( 577 ) $ 742
Net earnings 187 187
Other comprehensive (loss) income 13 13
Dividends ($ 0.96 per share declared)
( 123 ) ( 123 )
Stock-based compensation 16 16
Other employee stock plan activities 3 — 16 264 19
Treasury stock purchased ( 73 ) ( 466 ) ( 73 )
Balance as of March 31, 2019 $ 159 158,741 $ 1,033 $ 3,004 $ ( 2,851 ) ( 30,853 ) $ ( 564 ) $ 781
Balance as of December 31, 2019 $ 159 158,741 $ 1,062 $ 3,292 $ ( 3,357 ) ( 33,717 ) $ ( 601 ) $ 555
Net earnings 241 241
Other comprehensive (loss) income ( 55 ) ( 55 )
Dividends ($ 1.06 per share declared)
( 135 ) ( 135 )
Stock-based compensation 18 18
Other employee stock plan activities 31 — 70 1,083 101
Treasury stock purchased ( 30 ) ( 184 ) ( 30 )
Balance as of March 31, 2020 $ 159 158,741 $ 1,111 $ 3,398 $ ( 3,317 ) ( 32,818 ) $ ( 656 ) $ 695
Nine Months Ended March 31
Common Stock Additional Paid-in Capital Retained Earnings Treasury Stock Accumulated
Other
Comprehensive
Net (Loss) Income
Total Stockholders ’ Equity
Amount Shares
(in thousands) 		Amount Shares
(in thousands)
Balance as of June 30, 2018 $ 159 158,741 $ 975 $ 2,797 $ ( 2,658 ) ( 30,759 ) $ ( 547 ) $ 726
Cumulative effect of accounting changes, net of tax (1)
( 3 ) ( 3 )
Net earnings 579 579
Other comprehensive (loss) income ( 17 ) ( 17 )
Dividends ($ 2.88 per share declared)
( 369 ) ( 369 )
Stock-based compensation 34 34
Other employee stock plan activities 24 — 116 2,048 140
Treasury stock purchased ( 309 ) ( 2,142 ) ( 309 )
Balance as of March 31, 2019 $ 159 158,741 $ 1,033 $ 3,004 $ ( 2,851 ) ( 30,853 ) $ ( 564 ) $ 781
Balance as of June 30, 2019 $ 159 158,741 $ 1,046 $ 3,150 $ ( 3,194 ) ( 33,055 ) $ ( 602 ) $ 559
Cumulative effect of accounting changes, net of tax (2)
22 22
Net earnings 629 629
Other comprehensive (loss) income ( 54 ) ( 54 )
Dividends ($ 3.18 per share declared)
( 402 ) ( 402 )
Stock-based compensation 37 37
Other employee stock plan activities 28 ( 1 ) 96 1,661 123
Treasury stock purchased ( 219 ) ( 1,424 ) ( 219 )
Balance as of March 31, 2020 $ 159 158,741 $ 1,111 $ 3,398 $ ( 3,317 ) ( 32,818 ) $ ( 656 ) $ 695

(1) As a result of adopting ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606),” on July 1, 2018, the Company recorded a cumulative effect of initially applying the new guidance as an adjustment to the fiscal year 2019 opening balance of Retained earnings.
(2) As a result of adopting ASU No. 2016-02, “Leases (Topic 842),” on July 1, 2019, the Company recorded a cumulative effect of initially applying the new guidance as an adjustment to the fiscal year 2020 opening balance of Retained earnings. See Note 1 for more information.
15
NOTE 9. STOCKHOLDERS’ EQUITY (Continued)
The Company has two stock repurchase programs: an open-market purchase program with an authorized aggregate purchase amount of up to $ 2,000 , which has no expiration date, and a program to offset the anticipated impact of dilution related to stock-based awards (the Evergreen Program), which has no authorization limit on the dollar amount and no expiration date.

Stock repurchases under the two stock repurchase programs were as follows for the periods indicated:
Three Months Ended Nine Months Ended
3/31/2020 3/31/2019 3/31/2020 3/31/2019
Amount Shares
(in thousands) 		Amount Shares
(in thousands) 		Amount Shares
(in thousands) 		Amount Shares
(in thousands)
Open-market purchase program $ — — $ — — $ 85 577 $ 78 591
Evergreen Program 30 184 73 466 134 847 231 1,551
Total stock repurchases $ 30 184 $ 73 466 $ 219 1,424 $ 309 2,142
16
NOTE 9. STOCKHOLDERS’ EQUITY (Continued)
Changes in Accumulated other comprehensive net (loss) income by component were as follows for the periods indicated:
Three Months Ended March 31
Foreign currency translation adjustments Net unrealized gains (losses) on derivatives Pension and postretirement benefit adjustments Accumulated other comprehensive net (loss) income
Balance as of December 31, 2018 $ ( 415 ) $ ( 26 ) $ ( 136 ) $ ( 577 )
Other comprehensive (loss) income before reclassifications 8 2 — 10
Amounts reclassified from Accumulated other comprehensive net (loss) income — 2 2 4
Income tax benefit (expense) — ( 1 ) — ( 1 )
Net current period other comprehensive (loss) income 8 3 2 13
Balance as of March 31, 2019 $ ( 407 ) $ ( 23 ) $ ( 134 ) $ ( 564 )
Balance as of December 31, 2019 $ ( 421 ) $ ( 17 ) $ ( 163 ) $ ( 601 )
Other comprehensive (loss) income before reclassifications ( 49 ) ( 9 ) — ( 58 )
Amounts reclassified from Accumulated other comprehensive net (loss) income — 2 2 4
Income tax benefit (expense), and other ( 2 ) 2 ( 1 ) ( 1 )
Net current period other comprehensive (loss) income ( 51 ) ( 5 ) 1 ( 55 )
Balance as of March 31, 2020 $ ( 472 ) $ ( 22 ) $ ( 162 ) $ ( 656 )
Nine Months Ended March 31
Foreign currency translation adjustments Net unrealized gains (losses) on derivatives Pension and postretirement benefit adjustments Accumulated other comprehensive net (loss) income
Balance as of June 30, 2018 $ ( 384 ) $ ( 25 ) $ ( 138 ) $ ( 547 )
Other comprehensive (loss) income before reclassifications ( 22 ) ( 3 ) — ( 25 )
Amounts reclassified from Accumulated other comprehensive net (loss) income — 4 5 9
Income tax benefit (expense) ( 1 ) 1 ( 1 ) ( 1 )
Net current period other comprehensive (loss) income ( 23 ) 2 4 ( 17 )
Balance as of March 31, 2019 $ ( 407 ) $ ( 23 ) $ ( 134 ) $ ( 564 )
Balance as of June 30, 2019 $ ( 414 ) $ ( 23 ) $ ( 165 ) $ ( 602 )
Other comprehensive (loss) income before reclassifications ( 55 ) ( 6 ) — ( 61 )
Amounts reclassified from Accumulated other comprehensive net (loss) income — 6 5 11
Income tax benefit (expense), and other ( 3 ) 1 ( 2 ) ( 4 )
Net current period other comprehensive (loss) income ( 58 ) 1 3 ( 54 )
Balance as of March 31, 2020 $ ( 472 ) $ ( 22 ) $ ( 162 ) $ ( 656 )

Included in foreign currency translation adjustments are re-measurement losses on long-term intercompany loans where settlement is not planned or anticipated in the foreseeable future. For the three and nine months ended March 31, 2020, Other comprehensive (loss) income on these loans totaled $( 3 ) and $( 4 ), respectively. For the three and nine months ended March 31, 2019, Other comprehensive (loss) income on these loans totaled $ 1 and $( 3 ), respectively. There were no amounts associated with these loans reclassified from Accumulated other comprehensive net (loss) income for the periods presented.
17

NOTE 10. EMPLOYEE BENEFIT PLANS
The following table summarizes the components of net periodic benefit cost for the Company’s retirement income plans:
Three Months Ended Nine Months Ended
3/31/2020 3/31/2019 3/31/2020 3/31/2019
Service cost $ — $ — $ — $ —
Interest cost 5 5 15 17
Expected return on plan assets (1)
( 5 ) ( 4 ) ( 14 ) ( 13 )
Amortization of unrecognized items 3 2 7 7
Total $ 3 $ 3 $ 8 $ 11
(1) The weighted average long-term expected rate of return on plan assets used in computing the fiscal year 2020 net periodic benefit cost is 3.9 %.
The net periodic benefit cost for the Company’s retirement health care plans was $ 0 for both the three months ended March 31, 2020 and 2019, and $( 1 ) for both the nine months ended March 31, 2020 and 2019.
During the three months and nine months ended March 31, 2020, the Company made $ 7 and $ 10 in contributions to its domestic retirement income plans. During the three months and nine months ended March 31, 2019, the Company made $ 57 and $ 61 in contributions to its domestic retirement income plans.
Net periodic benefit costs are reflected in Other (income) expense, net.
18

NOTE 11. OTHER CONTINGENCIES AND GUARANTEES
Contingencies
The Company is involved in certain environmental matters, including response actions at various locations. The Company had recorded liabilities totaling $ 27 as of March 31, 2020 and June 30, 2019, for its share of aggregate future remediation costs related to these matters.
One matter, which accounted for $ 14 of the recorded liability as of March 31, 2020 and June 30, 2019, relates to environmental costs associated with one of the Company’s former operations at a site located in Alameda County, California. In November 2016, at the request of regulators and with the assistance of environmental consultants, the Company submitted a Feasibility Study that evaluated various options for managing the site and included estimates of the related costs. As a result, the Company recorded in Other (income) expense, net an undiscounted liability for costs estimated to be incurred over a 30 -year period, based on the option recommended in the Feasibility Study. However, as a result of ongoing discussions with regulators, in June 2017, the Company increased its recorded liability to $ 14 , which reflects anticipated costs to implement additional remediation measures at this site. While the Company believes its latest estimate is reasonable, regulators could require the Company to implement one of the other options evaluated in the Feasibility Study, with estimated undiscounted costs of up to $ 28 over an estimated 30 -year period, or require the Company to take other actions and incur costs not included in the study.
Another matter in Dickinson County, Michigan, at the site of one of the Company’s former operations for which the Company is jointly and severally liable, accounted for $ 10 and $ 11 of the recorded liability, as of March 31, 2020 and June 30, 2019, respectively. This amount reflects the Company’s agreement to be liable for 24.3 % of the aggregate remediation and associated costs for this matter pursuant to a cost-sharing arrangement with a third party. If the third party is unable to pay its share of the response and remediation obligations, the Company may be responsible for such obligations. With the assistance of environmental consultants, the Company maintains an undiscounted liability representing its current best estimate of its share of the capital expenditures, maintenance and other costs that may be incurred over an estimated 30 -year remediation period. Although it is reasonably possible that the Company’s exposure may exceed the amount recorded for the Dickinson County matter, any amount of such additional exposures, or range of exposures, is not estimable at this time. The Company’s estimated losses related to these matters are sensitive to a variety of uncertain factors, including the efficacy of any remediation efforts, changes in any remediation requirements, and the future availability of alternative clean-up technologies.
The Company is subject to various legal proceedings, claims and other loss contingencies, including, without limitation, loss contingencies relating to contractual arrangements, product liability, patents and trademarks, advertising, labor and employment, environmental, health and safety and other matters. With respect to these proceedings, claims and other loss contingencies, while considerable uncertainty exists, in the opinion of management at this time, the ultimate disposition of these matters, to the extent not previously provided for, will not have a material adverse effect, either individually or in the aggregate, on the Company’s condensed consolidated financial statements taken as a whole.
Guarantees
In conjunction with divestitures and other transactions, the Company may provide typical indemnifications (e.g., indemnifications for representations and warranties and retention of previously existing environmental, tax and employee liabilities) that have terms that vary in duration and in the potential amount of the total obligation and, in many circumstances, are not explicitly defined. The Company has not made, nor does it believe that it is probable that it will make, any material payments relating to its indemnifications, and believes that any reasonably possible payments would not have a material adverse effect, either individually or in the aggregate, on the Company’s condensed consolidated financial statements taken as a whole.
The Company had not recorded any material liabilities on the aforementioned guarantees as of March 31, 2020 and June 30, 2019.
As of March 31, 2020, the Company was party to a letter of credit of $ 10 , related to one of its insurance carriers, of which $ 0 had been drawn upon.


19

NOTE 12. SEGMENT RESULTS
The Company operates through strategic business units (SBUs) that are aggregated into four reportable segments based on the economics and nature of the products sold: Cleaning, Household, Lifestyle and International.
Certain non-allocated administrative costs, interest income, interest expense and various other non-operating income and expenses are reflected in Corporate. Corporate assets include cash and cash equivalents, prepaid expenses and other current assets, property and equipment, other investments and deferred taxes.
The tables below present reportable segment information and a reconciliation of the segment information to the Company’s consolidated Net sales and Earnings before income taxes, with amounts that are not allocated to the reportable segments reflected in Corporate.
Net sales
Three Months Ended Nine Months Ended
3/31/2020 3/31/2019 3/31/2020 3/31/2019
Cleaning $ 671 $ 508 $ 1,734 $ 1,579
Household 500 489 1,241 1,324
Lifestyle 339 309 1,008 953
International 273 245 755 731
Corporate — — — —
Total $ 1,783 $ 1,551 $ 4,738 $ 4,587
Earnings (losses) before income taxes
Three Months Ended Nine Months Ended
3/31/2020 3/31/2019 3/31/2020 3/31/2019
Cleaning $ 231 $ 135 $ 556 $ 450
Household 107 93 169 198
Lifestyle 66 51 221 191
International 36 24 106 77
Corporate ( 143 ) ( 63 ) ( 262 ) ( 184 )
Total $ 297 $ 240 $ 790 $ 732

All intersegment sales are eliminated and are not included in the Company’s reportable segments’ net sales.
Net sales to the Company’s largest customer, Wal-Mart Stores, Inc. and its affiliates, as a percentage of consolidated net sales, were 25 % for each of the three and nine months ended March 31, 2020 and 2019.
20
NOTE 12. SEGMENT RESULTS (Continued)
The following table provides Net sales as a percentage of the Company’s consolidated net sales for the Company’s SBUs and for the periods indicated:
Net sales
Three Months Ended Nine Months Ended
3/31/2020 3/31/2019 3/31/2020 3/31/2019
Home Care 23 % 20 % 22 % 19 %
Laundry 9 % 8 % 9 % 9 %
Professional Products 6 % 5 % 6 % 6 %
Cleaning 38 % 33 % 37 % 34 %
Bags and Wraps 11 % 12 % 12 % 13 %
Cat Litter 7 % 8 % 7 % 8 %
Grilling 9 % 10 % 6 % 6 %
Digestive Health 1 % 2 % 1 % 2 %
Household 28 % 32 % 26 % 29 %
Food 8 % 9 % 9 % 9 %
Natural Personal Care 4 % 4 % 5 % 5 %
Water Filtration 4 % 3 % 4 % 3 %
Dietary Supplements 3 % 3 % 3 % 4 %
Lifestyle 19 % 19 % 21 % 21 %
International 15 % 16 % 16 % 16 %
Total 100 % 100 % 100 % 100 %

During the second quarter of fiscal year 2020, the Company’s Charcoal SBU within the Household reportable segment was renamed the Grilling SBU to reflect a broader strategic view of the category. There has been no change to the composition of the Grilling SBU or the Household reportable segment; therefore, no prior periods were restated .

21

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The Clorox Company
(Dollars in millions, except share and per share data)
Management’s Discussion and Analysis of Financial Condition and Results of Operations (MD&A) is designed to provide a reader of The Clorox Company’s (the Company or Clorox) financial statements with a narrative from the perspective of management on the Company’s financial condition, results of operations, liquidity and certain other factors that may affect future results. The following discussion of the Company’s financial condition and results of operations should be read in conjunction with MD&A and the consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2019, which was filed with the Securities and Exchange Commission (SEC) on August 14, 2019, and the unaudited condensed consolidated financial statements and related notes contained in this Quarterly Report on Form 10-Q (this Report). Unless otherwise noted, MD&A compares the three and nine month periods ended March 31, 2020 (the current period) to the three and nine month periods ended March 31, 2019 (the prior period), with percentage and basis point calculations based on rounded numbers, except for per share data and the effective tax rate.

EXECUTIVE OVERVIEW
Clorox is a leading multinational manufacturer and marketer of consumer and professional products with approximately 8,800 employees worldwide. Clorox sells its products primarily through mass retailers, grocery outlets, warehouse clubs, dollar stores, home hardware centers, drug, pet and military stores, third-party and owned e-commerce channels, and distributors. Clorox markets some of the most trusted and recognized consumer brand names, including its namesake bleach and cleaning products, Pine-Sol ® cleaners, Liquid-Plumr ® clog removers, Poett ® home care products, Fresh Step ® cat litter, Glad ® bags, wraps and containers, Kingsford ® grilling products, Hidden Valley ® dressings and sauces, Brita ® water-filtration products, Burt’s Bees ® natural personal care products, RenewLife ® digestive health products, and Rainbow Light ® , Natural Vitality ™ and NeoCell ® dietary supplements. The Company also markets industry-leading products and technologies for professional customers, including those sold under the CloroxPro ™ and the Clorox Healthcare ® brand names. The Company has operations in more than 25 countries or territories and sells its products in more than 100 markets.
The Company primarily markets its leading brands in midsized categories considered to be financially attractive. Most of the Company’s products compete with other nationally advertised brands within each category and with “private label” brands.
The Company operates through strategic business units (SBUs) that are aggregated into the following four reportable segments based on the economics and nature of the products sold. During the second quarter of fiscal year 2020, the Company’s Charcoal SBU within the Household reportable segment was renamed the Grilling SBU to reflect a broader strategic view of the category. There has been no change to the composition of the Grilling SBU or the Household reportable segment; therefore, no prior periods were restated.
• Cleaning consists of Laundry, Home Care and Professional Products marketed and sold in the United States. Products within this segment include laundry additives, such as bleach products under the Clorox ® brand and Clorox 2 ® stain fighter and color booster; home care products, primarily under the Clorox ® , Formula 409 ® , Liquid-Plumr ® , Pine-Sol ® , S.O.S ® and Tilex ® brands; naturally derived products under the Green Works ® brand; and professional cleaning, disinfecting and food service products under the CloroxPro ™ , Dispatch ® , Clorox Healthcare ® , Hidden Valley ® and KC Masterpiece ® brands.
• Household consists of Grilling products, Bags and Wraps, Cat Litter, and Digestive Health products marketed and sold in the United States. Products within this segment include grilling products under the Kingsford ® and Match Light ® brands; bags, wraps and containers under the Glad ® brand; cat litter products under the Fresh Step ® , Scoop Away ® and Ever Clean ® brands; and digestive health products under the RenewLife ® brand.
• Lifestyle consists of Food products, Water Filtration systems and filters, Natural Personal Care products, and Dietary Supplements marketed and sold mainly in the United States. Products within this segment include dressings and sauces, primarily under the Hidden Valley ® , KC Masterpiece ® , Kingsford ® and Soy Vay ® brands; water-filtration systems and filters under the Brita ® brand; natural personal care products under the Burt’s Bees ® brand; and dietary supplements under the Rainbow Light ® , Natural Vitality ™ and NeoCell ® brands.
22

• International consists of products sold outside the United States. Products within this segment include laundry; home care; water filtration systems and filters; digestive health products; grilling products; cat litter products; food products; bags, wraps and containers; natural personal care products; and professional cleaning and disinfecting products primarily under the Clorox ® , Glad ® , PinoLuz ® , Ayudin ® , Limpido ® , Clorinda ® , Poett ® , Mistolin ® , Lestoil ® , Bon Bril ® , Brita ® , Green Works ® , Pine-Sol ® , Agua Jane ® , Chux ® , RenewLife ® , Kingsford ® , Fresh Step ® , Scoop Away ® , Ever Clean ® , KC Masterpiece ® , Hidden Valley ® , Burt’s Bees ® , CloroxPro ™ , and Clorox Healthcare ® brands.

RECENT EVENTS RELATED TO COVID-19
The novel coronavirus (COVID-19) pandemic has caused a severe global health crisis, along with economic and societal disruptions and uncertainties. As a result, we have taken an active role in addressing the ongoing pandemic’s impact on our employees, operations, customers, and consumers, including taking precautionary measures, such as implementing contingency plans, and making operational adjustments where necessary. The impact of COVID-19 and responses of governments, consumers, and others to the pandemic are affecting our business in many ways; however, we believe that the actions we are taking will help us emerge from this global pandemic operationally sound, and well positioned for continued long-term growth.
Commitment to Support People and Public Health
Our top priorities, from the beginning of this pandemic, have been the health and safety of our employees, our consumers, workers at healthcare facilities, and our communities. For example, we have taken extra precautions at our offices and manufacturing and distribution facilities, consistent with guidance from global, federal and local health authorities, such as social distancing, thermal scanning and partitions in our facilities. We have also implemented global travel restrictions and work-from-home policies for those employees who have the ability to work remotely. In addition, we have enhanced pay for our production employees, provided greater flexibility around sick-pay and work hours and established an employee emergency relief fund to provide COVID-19 related support to our employees. Furthermore, we and our foundations have made cash and product donations to various organizations to help front-line workers and communities respond to COVID-19.
Increasing our Capacity to Provide Needed Products and Changes in Costs
We have significantly increased our manufacturing production capacity for disinfecting cleaning products that are needed during this global health crisis and expect to continue to expand our production capacity for such products over the balance of the calendar year. We have done this, in part, by prioritizing the production of certain high-volume disinfecting cleaning products through significant reduction in the number of different types and sizes of disinfecting cleaning products we currently produce, by increasing production at our third party contract manufacturers and by reducing production employee changeover while managing social distancing. While we have experienced temporary closures of certain facilities, we have not experienced a material impact from a plant closure to date, and all of our plants and the vast majority of our contract manufacturers and suppliers continue to operate.
To date, we have had no material disruption in our access to necessary raw materials and other supplies or with our distribution network; however, we have experienced higher costs in certain areas as a result of COVID-19, such as transportation, logistics and production employee compensation, as well as incremental costs associated with newly added health screenings and enhanced cleaning and sanitation protocols to protect our employees at our facilities. In the future, we may decide to implement additional precautionary measures or operational adjustments as we deem prudent to meet consumer demand or help further ensure employee safety.

Other COVID-19 Items
For our fiscal third quarter ended March 31, 2020, we experienced increased demand for many of our products, especially our disinfecting cleaning products, in response to COVID-19, and expect strong demand for such products will continue throughout the rest of this fiscal year. Nevertheless, the extent of COVID-19’s effect on our operational and financial performance for the remainder of fiscal year 2020 and beyond will depend on future developments, including the duration, spread and intensity of the pandemic, our continued ability to manufacture and distribute our products, as well as any future government actions affecting consumers and the economy generally, all of which are uncertain and difficult to predict considering the rapidly evolving landscape.
COVID-19 has also impacted financial markets, and as such, in March 2020, we took certain actions to provide the Company with additional liquidity and flexibility, as described in the “Financial Position and Liquidity” section below. We will continue to actively monitor the potential impacts of COVID-19 on the commercial paper, credit and capital markets.

For further discussion of the possible impacts of the COVID-19 pandemic on our business, financial conditions and results of operations, see “Risk Factors” in Part II, Item 1A of this Report.

23

RESULTS OF OPERATIONS
CONSOLIDATED RESULTS
Three Months Ended Nine Months Ended
3/31/2020 3/31/2019 % Change 3/31/2020 3/31/2019 % Change
Net sales $ 1,783 $ 1,551 15 % $ 4,738 $ 4,587 3 %

Three Months Ended March 31, 2020
Percentage change versus the year-ago period
Reported (GAAP) Net Sales Growth / (Decrease) Reported Volume Acquisitions & Divestitures Foreign Exchange Impact
Price/Mix/Other (1)
Organic Sales Growth / (Decrease) (Non-GAAP) (2)
Organic Volume (3)
Cleaning 32 % 34 % — % — % (2) % 32 % 34 %
Household 2 5 — — (3) 2 5
Lifestyle 10 7 — — 3 10 7
International 11 16 — (11) 6 22 16
Total 15 % 18 % — % (2) % (1) % 17 % 18 %
Nine Months Ended March 31, 2020
Percentage change versus the year-ago period
Reported (GAAP) Net Sales Growth / (Decrease) Reported Volume Acquisitions & Divestitures Foreign Exchange Impact
Price/Mix/Other (1)
Organic Sales Growth / (Decrease) (Non-GAAP) (2)
Organic Volume (3)
Cleaning 10 % 12 % — % — % (2) % 10 % 12 %
Household (6) (2) — — (4) (6) (2)
Lifestyle 6 5 — — 1 6 5
International 3 6 — (9) 6 12 6
Total 3 % 6 % — % (2) % (1) % 5 % 6 %

(1) This represents the net impact on net sales growth / (decrease) from pricing actions, mix and other factors.
(2) Organic sales growth / (decrease) is defined as net sales growth / (decrease) excluding the effect of any acquisitions and divestitures as well as changes in foreign exchange rates. See “Non-GAAP Financial Measures” below for reconciliation of organic sales growth / (decrease) to net sales growth, the most directly comparable GAAP financial measure.
(3) Organic volume represents volume excluding the effect of any acquisitions and divestitures.

Net sales in the current quarter increased by 15%, reflecting higher shipments across all reportable segments driven by increased demand due to the COVID-19 pandemic. Volume increased by 18% and outpaced net sales growth due to the impact of unfavorable foreign currency exchange rates and unfavorable price mix.

Net sales in the current nine month period increased by 3%, reflecting higher shipments in the Cleaning, Lifestyle and International reportable segments, partially offset by lower shipments in the Household reportable segment. Volume increased by 6% and outpaced net sales growth due to the impact of unfavorable foreign currency exchange rates and unfavorable price mix.






24

Three Months Ended Nine Months Ended
3/31/2020 3/31/2019 % Change 3/31/2020 3/31/2019 % Change
Gross profit $ 832 $ 673 24 % $ 2,134 $ 1,994 7 %
Gross margin 46.7 % 43.4 % 45.0 % 43.5 %

Gross margin , defined as gross profit as a percentage of net sales, increased by 330 basis points in the current period from 43.4% to 46.7%. The increase was primarily driven by higher volume and cost savings, partially offset by higher trade promotion spending.

Gross margin increased by 150 basis points in the current nine month period from 43.5% to 45.0%. The increase was primarily driven by cost savings, higher volume and the benefit of price increases implemented to offset inflation occurring in specific international markets, partially offset by higher trade promotion spending and manufacturing and logistics costs.
Three Months Ended
% of Net Sales
3/31/2020 3/31/2019 % Change 3/31/2020 3/31/2019
Selling and administrative expenses $ 269 $ 216 25 % 15.1 % 13.9 %
Advertising costs 184 161 14 10.3 10.4
Research and development costs 39 34 15 2.2 2.2
Nine Months Ended
% of Net Sales
3/31/2020 3/31/2019 % Change 3/31/2020 3/31/2019
Selling and administrative expenses $ 690 $ 639 8 % 14.6 % 13.9 %
Advertising costs 461 445 4 9.7 9.7
Research and development costs 103 98 5 2.2 2.1

Selling and administrative expenses , as a percentage of net sales, increased by 120 basis points and 70 basis points in the current three and nine month periods, respectively. The increase in selling and administrative expenses was primarily due to higher incentive compensation expenses in both the current three and nine month periods, consistent with the Company’s performance-based compensation philosophy.

Advertising costs , as a percentage of net sales, remained essentially flat in the current three and nine month periods. The dollar increase in advertising expenses reflected the Company’s continued support behind its brands. The Company’s U.S. retail advertising spend as a percentage of net sales was approximately 12% and 11% in the current and year-ago quarters, respectively.

Research and development costs , as a percentage of net sales, remained essentially flat in the current three and nine month periods. The Company continues to focus on product innovation and cost savings .

Interest expense, Other (income) expense, net, and the effective tax rate on earnings
Three Months Ended Nine Months Ended
3/31/2020 3/31/2019 3/31/2020 3/31/2019
Interest expense $ 24 $ 24 $ 74 $ 72
Other (income) expense, net 19 (2) 16 8
Effective tax rate on earnings 18.9 % 21.8 % 20.4 % 20.8 %

Other (income) expense, net was $19 and $(2) in the current and prior three month periods, respectively, and $16 and $8 in the current and prior nine month periods, respectively. The variances were primarily due to the impact from the revaluation of the Company's trust assets related to its non-qualified deferred compensation plans (see Note 4 of the Notes to Condensed Consolidated Financial Statements).


25

The effective tax rate on earnings was 18.9% and 20.4% for the current three and nine month periods, respectively, and 21.8% and 20.8% for the prior three and nine month periods, respectively. The decrease in the effective tax rate on earnings for the current three month period was primarily due to higher excess tax benefits, partially offset by a lower benefit from the release of uncertain tax positions. The decrease for the current nine month period was primarily due to a higher benefit from the release of uncertain tax positions, partially offset by lower excess tax benefits.

Diluted net earnings per share
Three Months Ended Nine Months Ended
3/31/2020 3/31/2019 % Change 3/31/2020 3/31/2019 % Change
Diluted net earnings per share $ 1.89 $ 1.44 31 % $ 4.94 $ 4.45 11 %

Diluted net earnings per share (EPS) increased by $0.45, or 31%, in the current three month period, primarily due to net sales growth and gross margin expansion, partially offset by higher selling and administrative expenses and higher advertising investments.

Diluted net earnings per share increased by $0.49, or 11%, in the current nine month period, primarily due to gross margin expansion, partially offset by higher selling and administrative expenses.


SEGMENT RESULTS

The following presents the results of operations from the Company’s reportable segments and certain unallocated costs reflected in Corporate (see Notes to Condensed Consolidated Financial Statements for a reconciliation of segment results to consolidated results):

Cleaning
Three Months Ended Nine Months Ended
3/31/2020 3/31/2019 % Change 3/31/2020 3/31/2019 % Change
Net sales $ 671 $ 508 32 % $ 1,734 $ 1,579 10 %
Earnings before income taxes 231 135 71 556 450 24

Volume, sales and earnings before income taxes increased by 34%, 32% and 71%, respectively, in the current three month period. The volume increase was driven by higher shipments in all strategic business units, mainly due to increased demand in response to the COVID-19 pandemic. The higher shipments in Home Care and Laundry were primarily driven by elevated demand for Clorox ® disinfecting wipes, sprays and Clorox ® disinfecting bleach. The higher shipments of Professional Products reflect growth across all categories. Volume growth outpaced net sales growth, primarily due to unfavorable mix and higher trade promotion spending. The increase in earnings before income taxes was primarily due to net sales growth, partially offset by higher advertising investments.

Volume, net sales and earnings before income taxes increased by 12%, 10% and 24%, respectively, in the current nine month period. The volume increase was driven by higher shipments in all strategic business units, mainly due to increased demands as a result of the COVID-19 pandemic. The higher shipments in Home Care were primarily driven by strength in Clorox ® disinfecting wipes and sprays. The higher shipments of Professional Products reflect growth across all categories. Volume growth outpaced net sales growth, mainly due to unfavorable mix. The increase in earnings before income taxes was primarily due to net sales growth, cost savings and favorable commodity costs, partially offset by higher advertising investments.




26

Household
Three Months Ended Nine Months Ended
3/31/2020 3/31/2019 % Change 3/31/2020 3/31/2019 % Change
Net sales $ 500 $ 489 2 % $ 1,241 $ 1,324 (6) %
Earnings before income taxes 107 93 15 169 198 (15)

Volume, net sales and earnings before income taxes increased by 5%, 2% and 15%, respectively, in the current three month period. The volume increase was driven by higher shipments in Cat Litter and Grilling due to increased consumer demand, partially offset by lower shipments of RenewLife ® Digestive Health products. Volume growth outpaced net sales growth primarily due to higher trade promotion spending and unfavorable mix, partially offset by the benefit of price increases in Grilling implemented in the back half of fiscal year 2019. The increase in earnings before income taxes was mainly due to net sales growth and cost savings.

Volume, net sales and earnings before income taxes decreased by 2%, 6% and 15%, respectively, in the current nine month period. The volume decrease was mainly driven by lower shipments in Glad ® Bags and Wraps, mainly due to previous distribution losses, lower shipments of RenewLife ® Digestive Health products due to continued category and competitive headwinds and lower shipments in Grilling. These increases were partially offset by higher shipments in Cat Litter due to increased consumer demand. The variance between volume and net sales was primarily due to higher trade promotion spending. The decrease in earnings before income taxes was mainly due to lower net sales, partially offset by cost savings.

Lifestyle
Three Months Ended Nine Months Ended
3/31/2020 3/31/2019 % Change 3/31/2020 3/31/2019 % Change
Net sales $ 339 $ 309 10 % $ 1,008 $ 953 6 %
Earnings before income taxes 66 51 29 221 191 16

Volume, net sales and earnings before income taxes increased by 7%, 10% and 29%, respectively, in the current three month period. Both volume growth and net sales growth were primarily driven by higher shipments of Brita ® Water Filtration and Food products due to increased demand in light of the COVID-19 pandemic, partially offset by lower shipments in the Nutranext Dietary Supplements business due to a supply disruption related to the COVID-19 pandemic. Net sales growth outpaced volume growth, mainly due to favorable mix. The increase in earnings before income taxes was primarily due to net sales growth, partially offset by higher advertising investments.

Volume, net sales and earnings before income taxes increased by 5%, 6% and 16%, respectively, in the current nine month period. Both volume growth and net sales growth were driven by higher shipments of Brita ® Water Filtration, Food, and Burt’s Bees ® Natural Personal Care products, partially offset by lower shipments in the Nutranext Dietary Supplements business. Higher shipments of Brita ® Water Filtration and Food products were mainly driven by increased demand in light of the COVID-19 pandemic. Higher shipments of Burt’s Bees ® Natural Personal Care products were mainly driven by continued strength in lip and face care. The increase in earnings before income taxes was primarily due to net sales growth.






27

International
Three Months Ended Nine Months Ended
3/31/2020 3/31/2019 % Change 3/31/2020 3/31/2019 % Change
Net sales $ 273 $ 245 11 % $ 755 $ 731 3 %
Earnings before income taxes 36 24 50 106 77 38

Volume, net sales and earnings before income taxes increased by 16%, 11% and 50% respectively, in the current three month period. Volume increased primarily driven by higher shipments in Latin America and Canada. Volume growth outpaced net sales growth mainly due to the impact of unfavorable foreign currency exchange rates, partially offset by the benefit of price increases implemented to offset inflation. The increase in earnings before income taxes was primarily due to the net sales growth, partially offset by the impact of unfavorable foreign currency exchange rates, mainly in Argentina.

Volume, net sales and earnings before income taxes increased by 6%, 3% and 38% respectively, in the current nine month period. Volume increased primarily driven by higher shipments in Canada, Latin America and Australia. Volume growth outpaced net sales growth, mainly due to the impact of unfavorable foreign currency exchange rates, partially offset by the benefit of price increases implemented to offset inflation. The increase in earnings before income taxes was largely due to net sales growth, partially offset by the impact of unfavorable foreign currency exchange rates, mainly in Argentina.

Argentina

The business environment in Argentina continues to be challenging due to significant volatility in Argentina’s currency, high inflation, economic recession and additional uncertainty related to the impacts of COVID-19. The Company operates in Argentina through certain wholly owned subsidiaries (collectively, “Clorox Argentina”). Clorox Argentina manufactures products at two plants that it owns and operates across Argentina and markets those products to consumers throughout the country. Products are advertised nationally and sold to consumers through wholesalers and retail outlets located throughout Argentina. Sales are made primarily through the use of Clorox Argentina’s sales force. Small amounts of products produced in Argentina are exported each year, including sales to the Company’s other subsidiaries located primarily in Latin America. Clorox Argentina obtains its raw materials almost entirely from local sources; however, the price of some of these raw materials may fluctuate with changes in the value of the U.S. dollar against the Argentine peso. The Company also conducts research and development activities at its owned facility in Buenos Aires, Argentina. Additionally, Clorox Argentina performs marketing, legal, and various other shared service activities to support the Company’s International operations. Clorox Argentina, in turn, benefits from shared service activities performed within other geographic locations, such as information technology support and manufacturing technical assistance.

Effective July 1, 2018, under the requirements of U.S. GAAP, Argentina was designated as a highly inflationary economy, since it has experienced cumulative inflation of approximately 100 percent or more over a three year period. As a result, beginning July 1, 2018, the U.S. dollar replaced the Argentine peso as the functional currency of the Company’s subsidiaries in Argentina. Consequently, gains and losses from non-U.S. dollar denominated monetary assets and liabilities of Clorox Argentina are recognized in Other (income) expense, net in the condensed consolidated statement of earnings.

As of September 2019, the government of Argentina reinstated foreign exchange controls in response to further declines in the value of the Argentine peso, limiting the Company’s ability to convert Argentine pesos to U.S. dollars and transfer U.S. dollars outside of Argentina. As of March 31, 2020 and June 30, 2019, the net asset position, excluding goodwill, of Clorox Argentina was $44 and $47, respectively. Of these net assets, cash balances were approximately $13 and $16 as of March 31, 2020 and June 30, 2019, respectively. Net sales from Clorox Argentina represented approximately 2% of the Company’s consolidated net sales for both the nine months ended March 31, 2020 and the fiscal year ended June 30, 2019.

Volatility in the exchange rate is expected to continue in the future, which, along with competition, changes in the retail, labor and macro-economic environment, and implemented and future additional legal limitations instituted to restrict foreign exchange transactions, as well as government price controls, could have an adverse impact on Clorox Argentina’s liquidity, net sales, net earnings, cash flows and net monetary asset position. The Company is closely monitoring developments in Argentina and continues to take steps intended to mitigate the adverse conditions, but there can be no assurances that these actions will be able to mitigate these conditions as they may occur.


28

Corporate

Certain non-allocated administrative costs, interest income, interest expense, and various other non-operating income and expenses are reflected in Corporate. Corporate assets include cash and cash equivalents, prepaid expenses and other current assets, property and equipment, other investments, and deferred taxes.

Three Months Ended Nine Months Ended
3/31/2020 3/31/2019 % Change 3/31/2020 3/31/2019 % Change
Losses before income taxes $ (143) $ (63) 127 % $ (262) $ (184) 42 %

Losses before income taxes increased by $80 in the current three month period due to higher employee and incentive compensation expenses and COVID-19 related expenditures.

Losses before income taxes increased by $78 in the current nine month period due to higher employee and incentive compensation expenses and COVID-19 related expenditures.

29

FINANCIAL POSITION AND LIQUIDITY
The Company’s financial condition and liquidity remained strong as of March 31, 2020. The following table summarizes cash activities:
Nine Months Ended
3/31/2020 3/31/2019
Net cash provided by operations $ 806 $ 603
Net cash used for investing activities (145) (126)
Net cash used for financing activities (261) (429)

Operating Activities

Net cash provided by operations was $806 in the current nine month period, compared with $603 in the prior nine month period. The year-over-year increase was primarily due to decreases in working capital (higher receivables offset by lower inventories due primarily to an increase in quarter-end sales in the current year, and higher payables in the current year due to the timing of vendor payments), higher cash earnings and prior fiscal year’s voluntary increase in the Company’s contributions to the domestic retirement income plans.

Investing Activities

Net cash used for investing activities was $145 in the current nine month period, compared with $126 in the prior nine month period. The year-over-year increase was mainly due to higher capital spending in the current nine-month period, primarily driven by the acquisition of a manufacturing facility.

Financing Activities

Net cash used for financing activities was $261 in the current nine month period, compared with $429 in the prior nine month period. The year-over-year decrease was mainly due to an increase in cash sourced from short-term borrowings and lower treasury stock purchases, partially offset by increased cash dividend payments.

Capital Resources and Liquidity

Global financial markets have experienced a significant increase in volatility due to heightened uncertainty over the adverse economic impact caused by the COVID-19 outbreak. Notwithstanding these potential adverse market conditions, the Company believes it will have the funds necessary to support our short-term liquidity and operating needs based on our anticipated ability to generate positive cash flows from operations in the future, access to capital markets enabled by our strong short-term and long-term credit ratings, and current borrowing availability under the credit agreement.

Credit Arrangements

On November 15, 2019, the Company entered into a new $1,200 revolving credit agreement (the Credit Agreement) that matures in November 2024. The Credit Agreement replaced a prior $1,100 revolving credit agreement (the Prior Agreement) in place since February 2017. No termination fees or penalties were incurred in connection with entering the new Credit Agreement, which was considered a debt modification.

There was $450 outstanding under the Credit Agreement as of March 31, 2020, and no borrowings under the Prior Agreement as of June 30, 2019. The Company borrowed under the Credit Agreement primarily to pay down maturing commercial paper balances in light of current uncertainty in short-term credit markets resulting from the COVID-19 outbreak.

The Credit Agreement includes certain restrictive covenants and limitations. The primary restrictive covenant is a minimum ratio of 4.0 calculated as total earnings before interest, taxes, depreciation and amortization and non-cash asset impairment charges (Consolidated EBITDA) to total interest expense for the trailing four quarters (Interest Coverage ratio), as defined and described in the Credit Agreement.

30

The following table sets forth the calculation of the Interest Coverage ratio as of March 31, 2020, using Consolidated EBITDA for the trailing four quarters, as contractually defined in the Credit Agreement:
Twelve Months Ended
3/31/2020
Earnings from operations $ 870
Add back:
Interest expense 99
Income tax expense 212
Depreciation and amortization 180
Non-cash asset impairment charges 1
Deduct:
Interest income (2)
Consolidated EBITDA $ 1,360
Interest expense $ 99
Interest Coverage ratio 13.7

The Company was in compliance with all restrictive covenants and limitations in the Credit Agreement as of March 31, 2020, and anticipates being in compliance with all restrictive covenants for the foreseeable future. The Company continues to monitor the financial markets and assess its ability to continue to draw on its credit agreement, and currently expects it will continue to have access to borrowings under the Credit Agreement.

As of March 31, 2020, the Company maintained $38 of foreign and other credit lines, of which $2 was outstanding.

Stock Repurchases and Dividend Payments

As of March 31, 2020, the Company had two stock repurchase programs: an open-market purchase program with an authorized aggregate purchase amount of up to $2,000, which has no expiration date, and a program to offset the anticipated impact of dilution related to stock-based awards (the Evergreen Program), which has no authorization limit on the dollar amount and no expiration date.

Stock repurchases under the two stock repurchase programs were as follows for the periods indicated:
Three Months Ended Nine Months Ended
3/31/2020 3/31/2019 3/31/2020 3/31/2019
Amount Shares
(in thousands) 		Amount Shares
(in thousands) 		Amount Shares
(in thousands) 		Amount Shares
(in thousands)
Open-market purchase program $ — — $ — — $ 85 577 $ 78 591
Evergreen Program 30 184 73 466 134 847 231 1,551
Total stock repurchases $ 30 184 $ 73 466 $ 219 1,424 $ 309 2,142

Dividends per share declared and total dividends paid were as follows for the periods indicated:
Three Months Ended Nine Months Ended
3/31/2020 3/31/2019 3/31/2020 3/31/2019
Dividends per share declared $ 1.06 $ 0.96 $ 3.18 $ 2.88
Total dividends paid 133 123 399 368

31

CONTINGENCIES
See Notes to Condensed Consolidated Financial Statements for information on the Company’s contingencies.
RECENTLY ISSUED ACCOUNTING STANDARDS
See Notes to Condensed Consolidated Financial Statements for a summary of recently issued accounting standards relevant to the Company.
NON-GAAP FINANCIAL MEASURES

The non-GAAP financial measures that may be included in this MD&A and the reasons management believes they are useful to investors are described below. These measures should be considered supplemental in nature and are not intended to be a substitute for the related financial information prepared in accordance with U.S. GAAP. In addition, these measures may not be the same as similarly named measures presented by other companies.

The Company uses the term Consolidated EBITDA because it is a term used in its revolving credit agreement. As defined in the Credit Agreement, Consolidated EBITDA represents earnings before interest, taxes, depreciation and amortization and non-cash asset impairment charges. Interest Coverage ratio is the ratio of Consolidated EBITDA to interest expense. The Company’s management believes disclosure of Consolidated EBITDA provides useful information to investors because it is used in the primary restrictive covenant in the Credit Agreement. For additional discussion of the Interest Coverage ratio and a reconciliation of Consolidated EBITDA, see “ Financial Position and Liquidity - Financing Activities - Credit Arrangements ” above.

Organic sales growth / (decrease) is defined as net sales growth excluding the effect of foreign exchange rate changes and any acquisitions and divestitures. Management believes that the presentation of organic sales growth / (decrease) is useful to investors because it excludes sales from any acquisitions and divestitures, which results in a comparison of sales only from the businesses that the Company was operating throughout the relevant periods, and the impact of foreign exchange rate changes, which are out of the control of the Company and management.

The following table provides a reconciliation of organic sales growth / (decrease) (non-GAAP) to net sales growth / (decrease) (GAAP), the most comparable GAAP measure:
Three Months Ended March 31, 2020
Percentage change versus the year-ago period
Cleaning Household Lifestyle International Total
Net sales growth / (decrease) (GAAP) 32 % 2 % 10 % 11 % 15 %
Add: Foreign Exchange — — — 11 % 2 %
Add/(Subtract): Divestitures/Acquisitions — — — — —
Organic sales growth / (decrease) (non-GAAP) 32 % 2 % 10 % 22 % 17 %
Nine Months Ended March 31, 2020
Percentage change versus the year-ago period
Cleaning Household Lifestyle International Total
Net sales growth / (decrease) (GAAP) 10 % (6) % 6 % 3 % 3 %
Add: Foreign Exchange — — — 9 % 2 %
Add/(Subtract): Divestitures/Acquisitions — — — — —
Organic sales growth / (decrease) (non-GAAP) 10 % (6) % 6 % 12 % 5 %

32

Cautionary Statement
This Quarterly Report on Form 10-Q (this Report), including the exhibits hereto and the information incorporated by reference herein, contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, among others, statements related to the expected or potential impact of the novel coronavirus (COVID-19) pandemic, and the related responses of governments, consumers, customers, suppliers, employees and the Company, on our business, operations, employees, financial condition and results of operations, and any such forward-looking statements, whether concerning the COVID-19 pandemic or otherwise, involve risks, assumptions and uncertainties. Except for historical information, statements about future volumes, sales, organic sales growth, foreign currencies, costs, cost savings, margins, earnings, earnings per share, diluted earnings per share, foreign currency exchange rates, tax rates, cash flows, plans, objectives, expectations, growth or profitability are forward-looking statements based on management’s estimates, beliefs, assumptions and projections. Words such as “could,” “may,” “expects,” “anticipates,” “targets,” “goals,” “projects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “will,” “predicts,” and variations on such words, and similar expressions that reflect our current views with respect to future events and operational, economic and financial performance are intended to identify such forward-looking statements. These forward-looking statements are only predictions, subject to risks and uncertainties, and actual results could differ materially from those discussed. Important factors that could affect performance and cause results to differ materially from management’s expectations, or could affect the Company’s ability to achieve its strategic goals, are described in the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2019 and in this Report, as updated from time to time in the Company’s Securities and Exchange Commission filings. These factors include, but are not limited to, the uncertainties relating to the impact of COVID-19 on the Company’s business, operations, employees, financial condition and results of operations as well as:
• intense competition in the Company’s markets;
• the impact of the changing retail environment, including the growth of alternative retail channels and business models, and changing consumer preferences;
• volatility and increases in commodity costs such as resin, sodium hypochlorite and agricultural commodities, and increases in energy, transportation or other costs;
• the ability of the Company to drive sales growth, increase prices and market share, grow its product categories and manage favorable product and geographic mix;
• dependence on key customers and risks related to customer consolidation and ordering patterns;
• risks related to the Company’s use of and reliance on information technology systems, including potential security breaches, cyber-attacks, privacy breaches or data breaches that result in the unauthorized disclosure of consumer, customer, employee or Company information, or service interruptions;
• the Company’s ability to maintain its business reputation and the reputation of its brands and products;
• the impact of COVID-19 on the availability of, and efficiency of the supply, manufacturing and distribution systems for, the Company’s products, including any disruption to such systems;
• long-term changes in consumer preference or demand for our products as a result of any shortages or lack of availability of any products in the near-term;
• risks relating to acquisitions, new ventures and divestitures, and associated costs, including the potential for asset impairment charges related to, among others, intangible assets and goodwill; and the ability to complete announced transactions and, if completed, integration costs and potential contingent liabilities related to those transactions;
• lower revenue, increased costs or reputational harm resulting from government actions and regulations;
• the ability of the Company to successfully manage global political, legal, tax and regulatory risks, including changes in regulatory or administrative activity;
• uncertain worldwide, regional and local economic and financial market conditions, including as a result of fear of exposure to or actual impacts of a widespread disease outbreak, such as COVID-19;
• risks related to international operations and international trade, including foreign currency fluctuations, such as devaluations, and foreign currency exchange rate controls, including periodic changes in such controls; changes in U.S. immigration or trade policies, including the imposition of new or additional tariffs; labor claims and labor unrest; inflationary pressures, particularly in Argentina; political instability and the uncertainty regarding the outcome of Brexit; government-imposed price controls or other regulations; potential negative impact and liabilities from the use, storage and transportation of chlorine in certain international markets where chlorine is used in the production of bleach; widespread health emergencies, such as COVID-19; and the possibility of nationalization, expropriation of assets or other government action;
• the ability of the Company to innovate and to develop and introduce commercially successful products, or expand into adjacent categories and countries;
• the impact of product liability claims, labor claims and other legal or tax proceedings, including in foreign jurisdictions;
• the ability of the Company to implement and generate cost savings and efficiencies;
33

• the success of the Company’s business strategies;
• risks related to additional increases in the estimated fair value of P&G’s interest in the Glad ® business;
• the Company’s ability to attract and retain key personnel;
• supply disruptions , including as a result of COVID-19 and governments’ responses thereto, and other risks inherent in reliance on a limited base of suppliers;
• environmental matters, including costs associated with the remediation and monitoring of past contamination, and possible increases in costs resulting from actions by relevant regulators, and the handling and/or transportation of hazardous substances;
• increased focus by governmental and non-governmental organizations, customers, consumers and investors on sustainability issues, including those related to climate change;
• the facilities of the Company and its suppliers being subject to disruption by events beyond the Company’s control, including work stoppages, cyber-attacks, natural disasters, disease outbreaks or pandemics, such as COVID-19, and terrorism;
• the Company’s ability to maximize, assert and defend its intellectual property rights;
• any infringement or claimed infringement by the Company of third-party intellectual property rights;
• the accuracy of the Company’s estimates and assumptions on which its financial projections are based;
• the effect of the Company’s indebtedness and credit rating on its business operations and financial results;
• the Company’s ability to access capital markets and other funding sources, as well as continued or increased market volatility;
• the Company’s ability to pay and declare dividends or repurchase its stock in the future;
• uncertainties relating to tax positions, tax disputes and changes in the Company’s tax rate, and any additional effects of the Tax Act on the Company;
• the Company’s ability to maintain an effective system of internal controls;
• the impacts of potential stockholder activism; and
• risks related to the Company’s discontinuation of operations in Venezuela.
The Company’s forward-looking statements in this Report are based on management’s current views, beliefs, assumptions and expectations regarding future events and speak only as of the date of this Report. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by the federal securities laws.
In this Report, unless the context requires otherwise, the terms “the Company,” “Clorox,” “we,” “us,” and “our” refer to The Clorox Company and its subsidiaries.

Item 3. Quantitative and Qualitative Disclosures About Market Risk
There have not been any material changes to the Company’s market risk since June 30, 2019. For additional information, refer to “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in Exhibit 99.1 of the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2019.

Item 4. Controls and Procedures
The Company’s management, with the participation of the Company’s Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the Company’s disclosure controls and procedures as of the end of the period covered by this Report. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the Company’s disclosure controls and procedures, as of the end of the period covered by this Report, were effective such that the information required to be disclosed by the Company in reports filed under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (ii) accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.
No change in the Company’s internal control over financial reporting occurred during the third fiscal quarter of the fiscal year ending June 30, 2020, that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.
34

PART II – OTHER INFORMATION
Item 1.A. Risk Factors
For information regarding Risk Factors, please refer to Item 1.A. in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2019, as supplemented by the following additional risk factor, and the information in “Cautionary Statement” included in this Report.
The currently evolving situation related to the COVID-19 pandemic could adversely affect the Company’s business, financial condition and results of operations.
In January 2020, the World Health Organization declared the novel coronavirus (“COVID-19”) outbreak to be a public health emergency and, in March 2020, it declared the outbreak to be a pandemic. The COVID-19 outbreak has caused severe global economic and societal disruptions and uncertainties. In response to the virus, countries and local governments have placed tens of millions of people under lockdown, and imposed travel restrictions and restrictions on the operation of non-essential businesses and services. Companies are also taking precautions, such as requiring employees to work remotely and temporarily closing businesses. These continuing restrictions, and future prevention and mitigation measures imposed by governments and private companies, are likely to continue to have a severe adverse impact on global economic conditions and consumer confidence and spending, which could adversely affect the Company’s business, financial condition and results of operations.
In addition, the COVID-19 pandemic may negatively impact our business by causing or contributing to, among other things, the following:
• Significant disruptions to our manufacturing, distribution and supply operations, including closure of our significant manufacturing and distribution facilities. Such significant disruptions could be due to, among other things, the loss or disruption of the timely availability of adequate supplies of essential raw materials or other manufacturing components; a decrease in our workforce or in the efficiency of our workforce, including as a result of illness to our employees or their families or governmental restrictions on our employees’ ability to travel or perform necessary business functions or as a result of the need for us to operate our business with substantial modifications to employee travel, employee work locations, and virtualization or cancellation of certain sales and marketing events; transportation and logistics challenges, including as a result of port and border closures and other governmental restrictions and the availability and capacity of shipping channels as consumers may shift to increased online shopping; and the loss or disruption of other manufacturing, distribution and supply capabilities.
• Cessation or significant reductions in the operations of, or the inability, or significant disruptions in the ability, to meet obligations to us of significant third-party suppliers, vendors and other business or commercial partners, which may be caused by their business, operational or financial difficulties, among other reasons.
• Significant decreases in sales of or demand for, or significant volatility in sales of or demand for, one or more of our significant products due to, among other things, closure or reduction in operating hours of our key customers; the temporary inability of consumers to purchase our products due to illness or government implemented lockdowns, quarantine or other restrictions; changes in consumer behavior or preference, including as a result of shortages in any of our products, decreased availability of our products in the near-term leading to reduced preference or demand for such products in the long term, any negative impact to our reputation resulting from an adverse perception of our response to the pandemic, or product recommendations by public health officials; retailers or distributors modifying their restocking or fulfillment practices; or a recession, a depression or uncertainty in worldwide, regional and local economies and financial market conditions.
• Significant disruptions to our business operations due to, among other things, unavailability of key employees, including our executive officers and senior management team, as a result of illness to themselves or their families, any cyber-attack and other disruptions to informational technologies, especially when a large number of our employees are working remotely and accessing our technology infrastructure remotely; cancellation or other disruptions of sales and marketing events; disruptions to trade promotion initiatives; and any delays or modifications to any significant cost savings or other strategic initiatives. In addition, we have experienced higher costs in certain areas as a result of COVID-19 such as transportation and logistics and production employee compensation, as well as incremental costs associated with newly added health screenings and enhanced cleaning and sanitation protocols to protect our employees at our facilities, which we expect could continue or could increase in these or other areas. Furthermore, difficult economic conditions may have a negative impact on our ability to access capital markets and other funding sources, on acceptable terms or at all, should we seek any future financing.
• Additional or renewed significant governmental actions, both in the U.S. and in international markets where we manufacture, market and sell our products, including lockdowns, quarantines or other restrictions on the ability of our employees to travel or perform necessary business functions or our ability to manufacture, distribute, market or sell our products; changes in currency rates and commodity costs associated with governmental actions or general economic trends; or other limitations or restrictions on our ability to manufacture, distribute, market or sell our products or the ability of our suppliers, customers or third-party partners to effectively run their operations, which may negatively
35

impact our ability to manufacture, distribute, market and sell our products. In addition, an increase in regulatory restrictions or continued market volatility could hinder our ability to execute strategic business activities including any acquisitions and divestitures.
The extent of COVID-19’s effect on our operational and financial performance will depend on future developments, including the duration, spread and intensity of the pandemic, our continued ability to manufacture and distribute our products, as well as any future government actions affecting consumers and the economy generally, all of which are uncertain and difficult to predict considering the rapidly evolving landscape. We will continue to actively monitor the situation and may take further actions that alter our business operations as may be required by local, state, federal or foreign authorities or that we determine are in the best interests of our employees, consumers, customers or business partners. Although the potential effects that COVID-19 may have on the Company are not clear, such impacts could adversely affect the Company’s business, financial condition and results of operations.
The potential effects of COVID-19 also could impact many of our risk factors included in Item 1.A. in our Annual Report on Form 10-K for the fiscal year ended June 30, 2019. However, as the COVID-19 situation is unprecedented and continuously evolving, the potential impacts to such risk factors remain uncertain.
36

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

In May 2018, the Board of Directors authorized the Company to repurchase up to $2,000 million in shares of common stock on the open market (the 2018 Open-Market Program), which has no expiration date.

In August 1999, the Board of Directors authorized a stock repurchase program to reduce or eliminate dilution upon the issuance of common stock pursuant to the Company’s stock compensation plans (the Evergreen Program). In November 2005, the Board of Directors authorized the extension of the Evergreen Program to reduce or eliminate dilution in connection with issuances of common stock pursuant to the Company’s 2005 Stock Incentive Plan. The Evergreen Program has no expiration date and has no specified limit as to dollar amount and therefore is not included in column [d] below.

The following table sets forth the purchases of the Company’s securities by the Company and any affiliated purchasers within the meaning of Rule 10b-18(a)(3) (17 CFR 240.10b-18(a)(3)) during the third quarter of fiscal year 2020.
[a] [b] [c] [d]
Period Total Number of
Shares Purchased
(1) 		Average Price Paid
per Share (2) 		Total Number of
Shares Purchased as
Part of Publicly
Announced Plans or
Programs 		Maximum Number (or
Approximate Dollar
Value) of Shares that
May Yet Be Purchased
Under the Plans or
Programs
January 1 to 31, 2020 — $ — — $1,493 million
February 1 to 29, 2020 102,905 162.27 102,905 $1,493 million
March 1 to 31, 2020 80,897 162.48 80,897 $1,493 million
Total 183,802 $ 162.37 183,802
____________________

(1) All of the shares purchased in February and March 2020 were acquired pursuant to the Company’s 2018 Evergreen Program.
(2) Average price paid per share in the period includes commission.
37

Item 6. Exhibits
See Exhibit Index below, which is incorporated by reference herein.
EXHIBIT INDEX
Exhibit No.
101.SCH XBRL Taxonomy Extension Schema Document.
101.CAL XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB XBRL Taxonomy Extension Label Linkbase Document.
101.PRE XBRL Taxonomy Extension Presentation Linkbase Document.
104 Cover Page Interactive Data File (embedded within the Inline XBRL document and included in Exhibit 101).
38

SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
THE CLOROX COMPANY
(Registrant)
DATE: May 1, 2020 BY /s/ Jeffrey R. Baker
Jeffrey R. Baker
Vice President – Chief Accounting Officer and Corporate Controller

39
TABLE OF CONTENTS
Part I Financial InformationItem 1. Financial StatementsNote 1. Summary Of Significant Accounting PoliciesNote 1. Summary Of Significant Accounting Policies (continued)Note 2. Inventories, NetNote 3. Leases and Other CommitmentsNote 3. Leases and Other Commitments (continued)Note 4. Financial Instruments and Fair Value MeasurementsNote 4. Financial Instruments and Fair Value Measurements (continued)Note 5. DebtNote 6. Income TaxesNote 7. Net Earnings Per Share (eps)Note 8. Comprehensive IncomeNote 9. Stockholders EquityNote 9. StockholdersNote 9. Stockholders Equity (continued)Note 10. Employee Benefit PlansNote 11. Other Contingencies and GuaranteesNote 12. Segment ResultsNote 12. Segment Results (continued)Item 2. Management S Discussion and Analysis Of Financial Condition and Results Of OperationsItem 3. Quantitative and Qualitative Disclosures About Market RiskItem 4. Controls and ProceduresPart II Other InformationItem 1. A. Risk FactorsItem 2. Unregistered Sales Of Equity Securities and Use Of ProceedsItem 6. Exhibits

Exhibits

10.1 Second Amended and Restated Executive Change in Control Severance Plan, effective February 11, 2020 (filed as Exhibit 10.1 to the Current Report on Form 8-K, filed February 14, 2020, incorporated herein by reference). 10.2 Severance Plan for Clorox Executive Committee Members, second amended and restated effective as of February 11, 2020 (filed as Exhibit 10.2 to the Current Report on Form 8-K, filed February 14, 2020, incorporated herein by reference). 31.1 Certification by the Chief Executive Officer of the Company Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 31.2 Certification by the Chief Financial Officer of the Company Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 32 Certification by the Chief Executive Officer and Chief Financial Officer of the Company Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.